Anti-CD200r1 antibody and use thereof

WO2026219250A8PCT designated stage Publication Date: 2026-11-19BEIJING DANXU BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/090733
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-15
Filing Date
2026-04-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

In existing technologies, the role of CD200R1 in immune regulation and the tumor microenvironment has not been fully utilized, leading to the inhibition of immune cell activity and affecting the treatment effect.

Method used

Provide anti-CD200R1 antibodies or their antigen-binding fragments, containing heavy chain variable regions and light chain variable regions with specific amino acid sequences, for targeting CD200R1 and regulating immune cell activity.

Benefits of technology

By targeting CD200R1, the anti-tumor activity of immune cells is enhanced, improving the treatment efficacy of autoimmune diseases, inflammatory diseases, and neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are an anti-CD200R1 antibody and a use thereof, especially an anti-CD200R1 antibody or an antigen-binding fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody, a vector comprising the nucleic acid, and a host cell comprising the nucleic acid or vector. Further provided are a pharmaceutical composition and conjugate comprising the antibody, and a treatment method using the antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-CD200R1 antibodies and their uses

[0001] This application claims priority to Chinese invention application filed on April 15, 2025, with application number 2025104724299, entitled "Anti-CD200R1 Antibody and Its Use Thereof", the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention relates to anti-CD200R1 antibodies and the use of such antibodies, particularly their use in the treatment of inflammatory diseases, autoimmune diseases, allergic diseases and neurodegenerative diseases. Background Technology

[0003] CD200R1 is a type I transmembrane glycoprotein, primarily expressed in myeloid cells (such as macrophages, dendritic cells, and neutrophils) and certain T cell subsets. Several family molecules highly homologous to CD200R1, such as CD200RLa, have been identified. These molecules share structural similarities with CD200R1, particularly in the presence of an Ig domain in their extracellular region.

[0004] CD200R1 plays a crucial role in immune regulation, particularly in the tumor microenvironment. The interaction between CD200 and CD200R1 can influence the activity and function of immune cells, potentially impacting tumor growth and spread. In recent years, with in-depth research into the interaction between CD200R1 and its ligand CD200, the key role of CD200R1 in various diseases has become increasingly clear, including autoimmune diseases, tumors, and inflammatory diseases.

[0005] In autoimmune diseases, abnormal expression of CD200R1 is often closely related to the pathogenesis and progression of the disease. Furthermore, CD200R1 also plays an important role in the tumor immune microenvironment. Tumor cells interact with CD200R1 on tumor-infiltrating immune cells (such as macrophages and dendritic cells) by expressing CD200, thereby inhibiting the anti-tumor activity of immune cells. (Kotwica-Mojzych K, B, Mojzych M. CD200: CD200R Interactions and Their Importance in Immunoregulation. Int J Mol Sci. 2021 Feb 5; 22(4): 1602. doi: 10.3390 / ijms22041602. PMID: 33562512; PMCID: PMC7915401)

[0006] Therefore, antibody therapy targeting CD200R1 holds promise as a novel immunotherapy approach for related diseases. Summary of the Invention

[0007] In one aspect, the present invention provides an anti-CD200R1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

[0008] (1) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:301, 302 and 303 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:306, 307 and 308 respectively.

[0009] (2) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:301, 422 and 303 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:306, 307 and 308 respectively.

[0010] (3) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:31, 32 and 33 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:36, 37 and 38 respectively.

[0011] (4) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:41, 42 and 43 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:46, 47 and 48 respectively.

[0012] (5) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:51, 52 and 53 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:56, 57 and 58 respectively.

[0013] (6) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:61, 62 and 63 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:66, 67 and 68 respectively.

[0014] (7) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:71, 72 and 73 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:76, 77 and 78 respectively.

[0015] (8) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:81, 82 and 83 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:86, 87 and 88 respectively.

[0016] (9) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:91, 92 and 93 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:96, 97 and 98 respectively.

[0017] (10) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:101, 102 and 103 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:106, 107 and 108 respectively.

[0018] (11) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:111, 112 and 113 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:116, 117 and 118 respectively.

[0019] (12) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:121, 122 and 123 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:126, 127 and 128 respectively.

[0020] (13) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:131, 132 and 133 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:136, 137 and 138 respectively.

[0021] (14) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:141, 142 and 143 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:146, 147 and 148 respectively.

[0022] (15) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:151, 152 and 153 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:156, 157 and 158 respectively.

[0023] (16) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:161, 162 and 163 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:166, 167 and 168 respectively.

[0024] (17) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:171, 172 and 173 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:176, 177 and 178 respectively.

[0025] (18) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:181, 182 and 183 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:186, 187 and 188 respectively.

[0026] (19) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:191, 192 and 193 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:196, 197 and 198 respectively.

[0027] (20) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:201, 202 and 203 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:206, 207 and 208 respectively;

[0028] (21) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:211, 212 and 213 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:216, 217 and 218 respectively.

[0029] (22) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:221, 222 and 223 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:226, 227 and 228 respectively;

[0030] (23) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:231, 232 and 233 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:236, 237 and 238 respectively;

[0031] (24) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:241, 242 and 243 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:246, 247 and 248 respectively.

[0032] (25) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:251, 252 and 253 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:256, 257 and 258 respectively.

[0033] (26) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:261, 262 and 263 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:266, 267 and 268 respectively.

[0034] (27) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:271, 272 and 273 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:276, 277 and 278 respectively;

[0035] (28) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:281, 282 and 283 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:286, 287 and 288 respectively;

[0036] (29) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:291, 292 and 293 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:296, 297 and 298 respectively;

[0037] (30) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:311, 312 and 313 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:316, 317 and 318 respectively.

[0038] (31) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:321, 322 and 323 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:326, 327 and 328 respectively;

[0039] (32) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:331, 332 and 333 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:336, 337 and 338 respectively;

[0040] (33) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:341, 342 and 343 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:346, 347 and 348 respectively.

[0041] (34) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:351, 352 and 353 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:356, 357 and 358 respectively.

[0042] (35) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:361, 362 and 363 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:366, 367 and 368 respectively.

[0043] (36) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:371, 372 and 373 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:376, 377 and 378 respectively.

[0044] (37) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:381, 382 and 383 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:386, 387 and 388 respectively.

[0045] (38) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:391, 392 and 393 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:396, 397 and 398 respectively.

[0046] (39) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:401, 402 and 403 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:406, 407 and 408 respectively.

[0047] (40) The VH comprises HCDR1, HCDR2, and HCDR3 having amino acid sequences as shown in SEQ ID NO:411, 412, and 413, respectively; and the VL comprises LCDR1, LCDR2, and LCDR3 having amino acid sequences as shown in SEQ ID NO:416, 417, and 418, respectively; or

[0048] (41) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:481, 482 and 483 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:486, 487 and 488 respectively.

[0049] In some embodiments, the present invention provides an anti-CD200R1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

[0050] (1) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:300; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:305;

[0051] (2) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:420; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:425;

[0052] (3) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:430; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:435;

[0053] (4) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:440; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:445;

[0054] (5) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:450; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:455;

[0055] (6) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:460; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:465;

[0056] (7) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:30; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:35;

[0057] (8) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:40; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:45;

[0058] (9) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:50; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:55;

[0059] (10) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:60; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:65;

[0060] (11) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:70; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:75;

[0061] (12) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:80; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:85;

[0062] (13) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:90; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:95;

[0063] (14) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:100; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:105;

[0064] (15) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:110; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:115;

[0065] (16) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:120; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:125;

[0066] (17) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:130; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:135;

[0067] (18) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:140; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:145;

[0068] (19) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:150; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:155;

[0069] (20) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:160; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:165;

[0070] (21) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:170; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:175;

[0071] (22) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:180; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:185;

[0072] (23) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:190; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:195;

[0073] (24) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:200; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:205;

[0074] (25) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:210; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:215;

[0075] (26) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:220; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:225;

[0076] (27) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:230; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:235;

[0077] (28) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:240; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:245;

[0078] (29) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:250; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:255;

[0079] (30) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:260; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:265;

[0080] (31) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:270; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:275;

[0081] (32) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:280; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:285;

[0082] (33) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:290; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:295;

[0083] (34) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:310; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:315;

[0084] (35) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:320; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:325;

[0085] (36) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:330; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:335;

[0086] (37) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:340; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:345;

[0087] (38) The VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:350; and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:355;

[0088] (39) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:360; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:365;

[0089] (40) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:370; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:375;

[0090] (41) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:380; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:385;

[0091] (42) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:390; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:395;

[0092] (43) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:400; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:405;

[0093] (44) The VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:410; and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:415; or

[0094] (45) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:480; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:485.

[0095] In some embodiments, the antibodies provided by the present invention are mouse antibodies, chimeric antibodies, or humanized antibodies.

[0096] In some embodiments, the antibody of the present invention is an isotype selected from IgG, IgA, IgM, IgE and IgD.

[0097] In some embodiments, the antibody provided by the present invention is a subtype selected from IgG1, IgG2, IgG3 and IgG4.

[0098] In some embodiments, the antigen-binding fragments provided by the present invention are selected from Fab, Fab', F(ab')2, Fd, Fd', Fv, scFv, ds-scFv, and dAb.

[0099] In some embodiments, the antibody provided by the present invention is a monoclonal antibody, a bispecific antibody, or a multispecific antibody.

[0100] In some embodiments, the antibody provided by the present invention comprises a heavy chain (HC) and a light chain (LC), wherein:

[0101] (1) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:304; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:309;

[0102] (2) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:424; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:429;

[0103] (3) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:434; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:439;

[0104] (4) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:444; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:449;

[0105] (5) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:454; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:459;

[0106] (6) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:464; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:469;

[0107] (7) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:34; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:39;

[0108] (8) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:44; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:49;

[0109] (9) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:54; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:59;

[0110] (10) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:64; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:69;

[0111] (11) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:74; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:79;

[0112] (12) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:84; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:89;

[0113] (13) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:94; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:99;

[0114] (14) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:104; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:109;

[0115] (15) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:114; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:119;

[0116] (16) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:124; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:129;

[0117] (17) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:134; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:139;

[0118] (18) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:144; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:149;

[0119] (19) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:154; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:159;

[0120] (20) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:164; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:169;

[0121] (21) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:174; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:179;

[0122] (22) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:184; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:189;

[0123] (23) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:194; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:199;

[0124] (24) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:204; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:209;

[0125] (25) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:214; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:219;

[0126] (26) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:224; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:229;

[0127] (27) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:234; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:239;

[0128] (28) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:244; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:249;

[0129] (29) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:254; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:259;

[0130] (30) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:264; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:269;

[0131] (31) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:274; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:279;

[0132] (32) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:284; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:289;

[0133] (33) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:294; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:299;

[0134] (34) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:314; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:319;

[0135] (35) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:324; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:329;

[0136] (36) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:334; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:339;

[0137] (37) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:344; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:349;

[0138] (38) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:354; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:359;

[0139] (39) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:364; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:369;

[0140] (40) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:374; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:379;

[0141] (41) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:384; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:389;

[0142] (42) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:394; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:399;

[0143] (43) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:404; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:409;

[0144] (44) The HC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:414; and the LC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:419; or

[0145] (45) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:484; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:489.

[0146] In another aspect, the present invention provides bispecific antibodies comprising the antibodies disclosed herein or antigen-binding fragments thereof.

[0147] In another aspect, the present invention provides nucleic acids comprising encoding antibodies disclosed herein or antigen-binding fragments thereof, or bispecific antibodies disclosed herein.

[0148] In another aspect, the present invention provides a vector comprising the nucleic acids disclosed herein.

[0149] In another aspect, the present invention provides a host cell comprising the nucleic acids or vectors disclosed herein.

[0150] In another aspect, the present invention provides conjugates comprising an antibody disclosed herein or an antigen-binding fragment thereof or a bispecific antibody disclosed herein, and a chemical moiety conjugated thereto.

[0151] In another aspect, the present invention provides pharmaceutical compositions comprising (i) an antibody or antigen-binding fragment thereof disclosed herein, a bispecific antibody disclosed herein, or a conjugate disclosed herein; and optionally (ii) a pharmaceutically acceptable carrier or excipient.

[0152] In some embodiments, the pharmaceutical composition of the present invention further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from antibodies, chemotherapeutic agents, small molecule drugs, siRNA, and antisense oligonucleotides.

[0153] In another aspect, the present invention provides a method for treating a disease in a subject, comprising administering to the subject an effective amount of an antibody disclosed herein or an antigen-binding fragment thereof, a bispecific antibody disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein, wherein the disease is a CD200R1-mediated disease and / or a disease associated with CD200R1 expression.

[0154] In another aspect, the present invention provides a method for treating a disease in a subject, comprising administering to the subject an effective amount of an antibody disclosed herein or an antigen-binding fragment thereof, a bispecific antibody disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein, wherein the disease is a disease associated with interleukin-8 (IL-8) secretion.

[0155] In some implementations, the disease is selected from inflammatory diseases, autoimmune diseases, allergic diseases, and neurodegenerative diseases.

[0156] In some implementations, the disease is selected from multiple sclerosis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, colitis, atopic dermatitis, and Parkinson's disease. Attached Figure Description

[0157] The features and advantages of the invention can be understood by referring to the following detailed description of exemplary embodiments that utilize the principles of the invention and their accompanying drawings:

[0158] Figure 1 shows the binding of the antibody of the present invention to huCD200R1-HEK293 cells.

[0159] Figure 2 shows the binding of the antibody of the present invention to CynoCD200R1-HEK293 cells.

[0160] Figure 3 shows the binding of the antibody of the present invention to the huCD200R1 protein.

[0161] Figure 4 shows the binding of the antibody of the present invention to the CynoCD200R1 protein.

[0162] Figure 5 shows that the antibody of the present invention binds nonspecifically to HEK293 cells.

[0163] Figure 6 shows the antibody of the present invention inhibiting LPS-induced release of IL-8 from HuCD200R1-U937 cells.

[0164] Figure 7 shows the results of the antibody activity test that blocks the binding of CD200 to CD200R1.

[0165] Figure 8 shows the FAC test results of humanized antibodies binding to cells expressing antigens.

[0166] Figure 9 shows the inhibition of LPS-induced IL-8 release from HuCD200R1-U937 cells by humanized antibody.

[0167] Figure 10 shows the animal experimental protocol in the embodiment.

[0168] Figure 11 shows the therapeutic effects of each test group on the mouse model. Detailed Implementation

[0169] The above-described features and advantages of the present invention, as well as their additional features and advantages, will become more clearly understood below by taking into account the accompanying drawings and the detailed description of the following embodiments.

[0170] The embodiments described herein with reference to the accompanying drawings are illustrative, exemplary, and intended for a general understanding of the invention. These embodiments should not be construed as limiting the scope of the invention. Identical or similar elements and elements having the same or similar functions are represented by the same reference numerals throughout the specification.

[0171] Unless otherwise stated or defined, all terms used have the common meaning in the art as is clear to a person skilled in the art. For example, refer to standard manuals such as Leuenberger, H.G., Nagel, B. and Klbl, H. eds., "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Helvetica Chimica Acta (1995), CH-4010 Basel, Switzerland; Sambrook et al., "Molecular Cloning: A Laboratory Manual" (2nd Ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989); F. Ausubel et al., eds., "Current protocols in molecular biology", Green Publishing and Wiley InterScience, New York (1987); Roitt et al., "Immunology" (6th Ed.), Mosby / Elsevier, Edinburgh (2001); and Janeway et al., "Immunobiology" (6th Ed.), Garland Science Publishing / Churchill Livingstone, New York. York (2005), and the general background techniques cited above.

[0172] definition

[0173] As used herein, the singular forms “a,” “an,” and “the” include plural objects unless the context clearly indicates otherwise. Thus, for example, references to “an antibody” include a plural number of antibodies, and in some embodiments, references to “an antibody” include multiple antibodies, and so on.

[0174] Unless otherwise stated or defined, the term “comprising” and its variations such as “including” and “containing” should be understood to mean including the said element or step or group of elements or steps, but not excluding any other element or step or group of elements or steps.

[0175] As used herein, the term "antibody" should be understood in its broadest sense and includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, antibody fragments, and multispecific antibodies (e.g., bispecific antibodies) containing at least two antigen-binding regions. Antibodies may contain additional modifications, such as non-naturally occurring amino acids, mutations in the Fc region, and mutations in glycosylation sites. Antibodies also include post-translational modified antibodies, fusion proteins containing antigenic determinants of antibodies, and immunoglobulin molecules containing any other modifications to antigen recognition sites, provided that these antibodies exhibit the desired biological activity.

[0176] Immunoglobulin molecules have the ability to specifically bind to specific antigens. These molecules typically consist of two heavy (H) chains and two light (L) chains linked together by disulfide bonds. Each heavy chain consists of a heavy chain variable region (or domain) (abbreviated as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains: CH1, CH2, and CH3. Each light chain consists of a light chain variable region (or domain) (abbreviated as VL) and a light chain constant region. The light chain constant region consists of one domain: CL. The variable regions of both the antibody heavy and light chains contain binding domains that interact with the antigen. The antibody constant region mediates the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (such as effector cells) and components of the complement system such as C1q (the first component in the classical complement activation pathway).

[0177] The heavy chain of immunoglobulins can be divided into three functional regions: the Fd region, the hinge region, and the Fc region (crystallizable fragment). The Fd region contains the VH and CH1 domains and binds to the light chain to form the Fab (antigen-binding fragment). The Fc fragment is responsible for immunoglobulin effector functions, including, for example, complement binding and binding to homologous Fc receptors on effector cells. The hinge region, found in the IgG, IgA, and IgD immunoglobulin classes, acts as a flexible spacer, allowing the Fab portion to move freely in space relative to the Fc region. The hinge domain is structurally diverse, differing in sequence and length between immunoglobulin classes and subclasses.

[0178] According to crystallographic studies, the immunoglobulin hinge region can be further subdivided into three regions structurally and functionally: the upper hinge, the core hinge, and the lower hinge. The upper hinge includes the amino acid from the carboxyl terminus of CH1 to the first motility-restricting residue in the hinge, typically the first cysteine ​​residue forming an interchain disulfide bond between the two heavy chains. The length of the upper hinge region is related to the fragmental flexibility of the antibody. The core hinge region contains the interchain disulfide bonds. The lower hinge region connects to the amino terminus of the CH2 domain and includes residues within the CH2 domain. The conformational changes allowed by the structure and flexibility of the immunoglobulin hinge region polypeptide sequence can affect the effector function of the antibody's Fc moiety.

[0179] The light chain variable region (VL) or heavy chain variable region (VH) consists of a "framework" region separated by three "complementarity-determining regions" or "CDRs". The framework regions are used to align with the CDRs that specifically bind to the antigenic epitopes. The CDRs include the amino acid residues in the antibody that are primarily responsible for antigen binding. Both the VL and VH domains contain the following framework (FR) and CDR regions from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The CDR1, CDR2, and CDR3 of the VL domain are also referred to as LCDR1, LCDR2, and LCDR3, respectively, in this paper; and the CDR1, CDR2, and CDR3 of the VH domain are also referred to as HCDR1, HCDR2, and HCDR3, respectively, in this paper.

[0180] The amino acid sequence of each VL and VH domain is consistent with any conventional definition of a CDR. Conventional definitions include the Kabat definition (Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987 and 1991)), the Chothia definition (Chothia and Lesk, J. Mol. Biol. 196:901-917, 1987; Chothia et al., Nature 342:878-883, 1989); the complex of the Chothia Kabat CDR, where CDR-H1 is a complex of the Chothia CDR and the Kabat CDR; the AbM definition used by the Oxford Molecular antibody modeling software; and the CONTACT definition by Martin et al. (world wide web bioinfo.org.uk / abs). Kabat provides a widely used numbering convention (the Kabat numbering system) in which corresponding residues between different heavy chains or between different light chains are assigned the same number. This disclosure may use CDRs defined according to any of these numbering systems.

[0181] Table 1. Methods for defining antibody CDRs

[0182] Based on the amino acid sequence of the constant region of the antibody heavy chain, immunoglobulin molecules can be classified into five classes (isotypes): IgA, IgD, IgE, IgG, and IgM, and can be further divided into different subtypes, such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. Based on the amino acid sequence of the light chain, the antibody light chain can be divided into lambda (λ) chains and kappa (κ) chains.

[0183] As used herein, the term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous population of antibodies. That is, each antibody that makes up the population is identical, except for a small number of mutations that may be naturally present. Monoclonal antibodies are highly specific and target a single antigen. The term "monoclonal antibody" as used herein is not limited to antibodies produced by hybridoma technology, nor should it be construed as requiring antibodies to be produced by any particular method.

[0184] In the context of this invention, the term "bispecific antibody" should be understood as an antibody having two distinct antigen-binding regions defined by different antibody sequences. This can be understood as binding to different targets, but also includes binding to different epitopes of a single target. As used herein, the term "bispecific antibody" should be understood in its broadest sense, including full-length bispecific antibodies and their antigen-binding fragments. Bispecific antibodies may contain additional modifications, such as non-naturally occurring amino acids, mutations in the Fc region, and mutations at glycosylation sites. Bispecific antibodies also include post-translational modified antibodies, fusion proteins containing antibody antigenic determinants, and immunoglobulin molecules containing any other modifications to antigen recognition sites, provided that these antibodies exhibit the desired biological activity.

[0185] As used herein, the term "antigen-binding fragment" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind antigens. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.

[0186] Examples of antigen-binding fragments covered in the term "antigen-binding portion" of an antibody include: (i) Fab fragments, monovalent fragments consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments containing two Fab fragments linked by disulfide bonds in a hinge region; (iii) Fab' fragments, which are essentially Fab fragments with a partially hinge region; (iv) Fd fragments, consisting of VH and CH1 domains; (v) Fd' fragments, having VH and CH1 domains and one or more cysteine ​​residues at the C-terminus of the CH1 domain; (vi) Fv fragments, consisting of VL and VH domains in a single arm of an antibody; (vii) dAb fragments, consisting of a VH domain; (viii) separated complementarity-determining regions (CDRs); and (ix) nanobodies, heavy chain variable regions containing a single variable domain and two constant domains. Furthermore, although the two domains VL and VH of the Fv fragment are encoded by different genes, they can be linked via synthetic linkers using recombinant methods, enabling them to be made into a single protein chain where the VL and VH regions pair to form a monovalent molecule (called a single-chain Fv (scFv)). Such single-chain antibodies are also intended to be encompassed within the term "antigen-binding fragment" of antibody. Additionally, the term also includes "straight-chain antibodies" comprising a pair of tandem Fd fragments (VH-CH1-VH-CH1) that together form the antigen-binding region with a complementary light-chain polypeptide, as well as any modified forms of the aforementioned fragments that retain antigen-binding activity.

[0187] These antigen-binding fragments can be obtained using conventional techniques known to those skilled in the art, and their utility can be screened in the same manner as for intact antibodies.

[0188] In this application, the term "chimeric antibody" generally refers to an antibody in which the variable region is derived from one species and the constant region is derived from another species. Typically, the variable region is derived from an antibody from a laboratory animal such as a rodent ("parental antibody") and the constant region is derived from a human antibody, such that the resulting chimeric antibody is less likely to induce an adverse immune response in human individuals compared to parental (e.g., rabbit-derived) antibodies.

[0189] In this application, the term "humanized antibody" generally refers to an antibody in which some or all of the amino acids outside the CDR region of a non-human antibody (e.g., a rabbit antibody) are replaced by corresponding amino acids derived from human immunoglobulins. Small additions, deletions, insertions, substitutions, or modifications of amino acids within the CDR region are also permissible, as long as they retain the antibody's ability to bind to a specific antigen. Humanized antibodies may optionally contain at least a portion of the constant region of human immunoglobulins. "Humanized antibodies" retain antigen specificity similar to the original antibody. The "humanized" form of a non-human (e.g., rabbit) antibody may minimally contain a chimeric antibody with a sequence derived from a non-human immunoglobulin. In some cases, CDR region residues in a human immunoglobulin (receptor antibody) may be replaced with CDR region residues from a non-human species (donor antibody) (such as a mouse, rat, rabbit, or non-human primate) having the desired properties, affinity, and / or capabilities. In some cases, FR region residues in a human immunoglobulin may be replaced with corresponding non-human residues. Furthermore, humanized antibodies may contain amino acid modifications not found in receptor antibodies or in donor antibodies. These modifications can be made to further improve antibody performance, such as binding affinity.

[0190] As used herein, the term "binding" or "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its target antigen. The binding specificity of an antibody can be determined based on affinity and / or cohesion. Affinity represents the equilibrium constant (KD) for the dissociation of the antigen and antibody, and is a measure of the strength of binding between the antigenic determinant and the antigen-binding site of the antibody: the smaller the KD value, the stronger the binding between the antigenic determinant and the antibody. Alternatively, affinity can also be expressed as the affinity constant (KA), which is 1 / KD.

[0191] Affinity is a measure of the strength of binding between an antibody and its associated antigen. Affinity involves the affinity between the antigenic determinant and the antigen-binding site of the antibody, as well as the number of associated binding sites present on the antibody. Typically, antibody binding to an antigen will bind the antigen with the following dissociation constant (KD): 10 -5 M to 10 -12 M or smaller, and preferably 10 -7 M to 10 -12 M or smaller, and more preferably 10 -8 M to 10 -12 M, and / or having the following binding affinity: at least 10 7 M -1 Preferably at least 10 8 M -1 More preferably at least 10 9 M -1 such as at least 10 12 M -1 It is generally considered that anything greater than 10...-4 M of K D The value indicates nonspecific binding. Specific binding of an antibody to an antigen or antigenic determinant can be determined in any known suitable manner, including, for example, Scatchard analysis and / or competitive binding assays such as radioimmunoassay (RIA), enzyme immunoassay (EIA), and sandwich competitive assays, as well as various variants known in the art.

[0192] The term "epitope" refers to the site on an antigen where an antibody binds. Epitopes can be formed from consecutive amino acids or from discontinuous amino acids juxtaposed within the ternary folds of one or more proteins. Epitopes formed from consecutive amino acids (also known as linear epitopes) are generally preserved upon exposure to denaturing solvents, while epitopes formed from ternary folds (also known as conformational epitopes) are generally lost during treatment with denaturing solvents. Epitopes typically comprise at least three, more usually at least five, or eight to ten amino acids in a unique spatial conformation. Epitopes define the minimum binding site for antibodies and are therefore specific targets for antibodies or their antigen-binding fragments.

[0193] As used herein, the term "sequence identity" refers to the degree to which two sequences (amino acids) have identical residues at the same positions when aligned. For example, "an amino acid sequence is X% identical to SEQ ID NO:Y" means that the amino acid sequence has X% identity with SEQ ID NO:Y, and is described as X% of the residues in the amino acid sequence being identical to the residues of the sequence disclosed in SEQ ID NO:Y. Typically, such calculations are performed using computer programs. Exemplary programs for comparing and aligning sequence pairs include ALIGN (Myers and Miller, 1988), FASTA (Pearson and Lipman, 1988; Pearson, 1990), and gapped BLAST (Altschul et al., 1997), BLASTP, BLASTN, or GCG (Devereux et al., 1984).

[0194] Furthermore, when determining the degree of sequence identity between two amino acid sequences, those skilled in the art may consider so-called "conserved" amino acid substitutions, which can generally be described as amino acid substitutions in which an amino acid residue is replaced by another amino acid residue having a similar chemical structure, having little or no effect on the function, activity, or other biological properties of the polypeptide. Such conserved amino acid substitutions are well known in the art.

[0195] Such conservative substitutions are preferably substitutions in which one amino acid from the following groups (a) to (e) is replaced by another amino acid residue from the same group: (a) small aliphatic, nonpolar, or weakly polar residues: Ala, Ser, Thr, Pro, and Gly; (b) polar, negatively charged residues and their (uncharged) amides: Asp, Asn, Glu, and Gln; (c) polar, positively charged residues: His, Arg, and Lys; (d) large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and (e) aromatic residues: Phe, Tyr, and Trp.

[0196] The particularly preferred conservative substitutions are as follows: Ala to Gly or to Ser; Arg to Lys; Asn to Gln or to His; Asp to Glu; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or to Pro; His to Asn or to Gln; Ile to Leu or to Val; Leu to Ile or to Val; Lys to Arg, to Gln or to Glu; Met to Leu, to Tyr or to Ile; Phe to Met, to Leu or to Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp; and / or Phe to Val, to Ile or to Leu.

[0197] As used in this article, the term "carrier" is intended to refer to a nucleic acid molecule that is capable of transporting another nucleic acid to which it is attached.

[0198] As used in this article, the term "host cell" refers to a cell into which an expression vector has been introduced.

[0199] In this application, the term "conjugate" generally refers to a substance formed by linking an antibody to another chemical moiety. The chemical moiety can be a cytotoxic drug, an immunostimulatory molecule, or a detectable marker. The drug can be, for example, a microtubule inhibitor, an antibiotic, a DNA synthesis inhibitor, a topoisomerase inhibitor, an RNA polymerase II inhibitor, or an RNA spliceosome inhibitor.

[0200] In this application, the term "pharmaceutical composition" generally refers to a formulation which is present in a form that allows the biological activity of the active ingredient to be effective and does not contain any additional ingredients that would have unacceptable toxicity to the subject to which the composition will be administered.

[0201] The term “pharmaceutical acceptable” means that the carrier or excipient is compatible with the other components of the composition and is not substantially toxic to the recipient, and / or that such carrier or excipient is approved or may be used in pharmaceutical compositions for parenteral administration to humans.

[0202] In this application, the term "pharmaceutically acceptable carrier" generally includes pharmaceutically acceptable carriers, excipients, or stabilizers that are non-toxic to cells or mammals exposed to them at the doses and concentrations used. Typically, physiologically acceptable carriers are pH-buffered aqueous solutions. Examples of physiologically acceptable carriers may include buffers, antioxidants, low molecular weight (less than about 10 residues) peptides, proteins, hydrophilic polymers, amino acids, monosaccharides, disaccharides and other carbohydrates, chelating agents, sugar alcohols, salt-forming anti-charge ions such as sodium; and / or nonionic surfactants.

[0203] As used herein, the terms “treatment,” “therapy,” “treatment,” etc., refer to the administration of a drug or procedure for the purpose of achieving an effect. These effects may be preventative in the complete or partial prevention of a disease or its symptoms, and / or therapeutic in the partial or complete cure of a disease and / or its symptoms. As used herein, “treatment” may include the treatment of a disease or condition in mammals, particularly humans (e.g., autoimmune diseases), and includes: (a) preventing the onset of a disease or its symptoms in subjects who may be susceptible to the disease (e.g., including diseases that may be related to or caused by the primary disease) but have not yet been diagnosed with the disease; (b) suppressing the disease, i.e., preventing its development; and (c) alleviating the disease, i.e. leading to its remission. Treatment may refer to any indicator of success in the treatment, improvement, or prevention of a disease, including any objective or subjective parameter such as a reduction in symptoms; remission; elimination of disease symptoms or making the disease condition more tolerable for the patient; slowing the rate of deterioration or decline; or weakening the final stage of deterioration. Treatment or improvement of symptoms is based on one or more objective or subjective parameters; including the results of a physician’s examination. Therefore, the term "treatment" includes the administration of the antibodies, compositions, or conjugates disclosed herein to prevent or delay, alleviate, or prevent or inhibit the development of symptoms or conditions associated with a disease (e.g., illness). The term "therapeutic effect" refers to the reduction, elimination, or prevention of disease, disease symptoms, or disease side effects in a subject.

[0204] As used herein, the term "inflammatory disease" should be understood in its broadest sense, including inflammatory diseases and diseases that are precipitated by chronic inflammation. For example, an inflammatory disease can be one of those diseases or conditions characterized by one or more of the following signs: pain (pain caused by the production of harmful substances and nerve stimulation), fever (burning caused by vasodilation), redness (redness caused by vasodilation and increased blood flow), swelling (a lump caused by excessive inflow or restricted outflow of fluid), and loss of function (which may be partial or complete, temporary or permanent). Inflammation takes many forms and includes, but is not limited to, one or more of the following: acute, adhesive, atrophic, catarrhal, chronic, sclerotic, diffuse, pervasive, exudative, fibrinous, fibrotic, localized, granulomatous, proliferative, hypertrophic, interstitial, metastatic, necrotic, occlusive, parenchymal, plastic, generative, proliferative, pseudomembranous, suppurative, sclerotic, serofibrillar, serological, simple, specific, subacute, suppurative, toxic, traumatic, and / or ulcerative. Inflammatory diseases further include, but are not limited to, those affecting blood vessels (polyarteritis, etc.); those affecting joints (transient arthritis, crystalline arthritis, osteoarthritis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, Reiter's arthritis, etc.); those affecting the gastrointestinal tract (inflammatory bowel disease, Crohn's disease, ulcerative colitis, etc.); those affecting the skin (dermatitis, psoriasis, etc.); allergic airway diseases (asthma, etc.); or those affecting multiple organs and tissues (systemic lupus erythematosus). Furthermore, chronic inflammation can trigger a variety of diseases, such as cardiovascular disease, cancer, diabetes, chronic kidney disease, fibrosis (pulmonary fibrosis, etc.), chronic obstructive pulmonary disease, COVID-19, acne scars, atherosclerosis, non-alcoholic fatty liver disease, as well as autoimmune diseases and neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, etc.). These diseases triggered by chronic inflammation are also included within the definition of inflammatory diseases.

[0205] As used herein, the term "allergic disease" should be understood according to its meaning in the pharmaceutical field. Specifically, allergic diseases in the sense of this invention include diseases characterized by an allergic and / or atopic immunological response to an antigen, which causes allergic and / or atopic symptoms in patients with allergic diseases. Examples of allergic diseases include, but are not limited to, the following: allergic dermatitis, summer eczema, urticaria, equine respiratory distress syndrome, airway inflammatory diseases, recurrent airway obstruction, airway hyperresponsiveness, chronic obstructive pulmonary disease, and autoimmune inflammatory processes such as irritable bowel syndrome (IBS).

[0206] As used in this article, the term "effective dose" refers to a dose administered to a subject that is sufficient to treat the disease.

[0207] As used herein, the term “subject” refers to any mammalian subject for whom a diagnosis, treatment, or therapy is desired. For therapeutic purposes, “mammal” means any animal classified as a mammal, including humans, livestock, and laboratory, zoo, sport, or pet animals such as dogs, horses, cats, cattle, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys, etc.

[0208] Anti-CD200R antibody

[0209] In one aspect, the present invention provides an anti-CD200R1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

[0210] (1) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:301, 302 and 303 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:306, 307 and 308 respectively.

[0211] (2) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:301, 422 and 303 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:306, 307 and 308 respectively.

[0212] (3) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:31, 32 and 33 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:36, 37 and 38 respectively.

[0213] (4) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:41, 42 and 43 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:46, 47 and 48 respectively.

[0214] (5) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:51, 52 and 53 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:56, 57 and 58 respectively.

[0215] (6) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:61, 62 and 63 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:66, 67 and 68 respectively.

[0216] (7) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:71, 72 and 73 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:76, 77 and 78 respectively.

[0217] (8) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:81, 82 and 83 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:86, 87 and 88 respectively.

[0218] (9) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:91, 92 and 93 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:96, 97 and 98 respectively.

[0219] (10) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:101, 102 and 103 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:106, 107 and 108 respectively.

[0220] (11) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:111, 112 and 113 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:116, 117 and 118 respectively.

[0221] (12) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:121, 122 and 123 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:126, 127 and 128 respectively.

[0222] (13) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:131, 132 and 133 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:136, 137 and 138 respectively.

[0223] (14) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:141, 142 and 143 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:146, 147 and 148 respectively.

[0224] (15) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:151, 152 and 153 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:156, 157 and 158 respectively.

[0225] (16) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:161, 162 and 163 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:166, 167 and 168 respectively.

[0226] (17) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:171, 172 and 173 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:176, 177 and 178 respectively.

[0227] (18) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:181, 182 and 183 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:186, 187 and 188 respectively.

[0228] (19) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:191, 192 and 193 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:196, 197 and 198 respectively.

[0229] (20) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:201, 202 and 203 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:206, 207 and 208 respectively;

[0230] (21) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:211, 212 and 213 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:216, 217 and 218 respectively.

[0231] (22) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:221, 222 and 223 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:226, 227 and 228 respectively;

[0232] (23) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:231, 232 and 233 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:236, 237 and 238 respectively;

[0233] (24) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:241, 242 and 243 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:246, 247 and 248 respectively.

[0234] (25) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:251, 252 and 253 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:256, 257 and 258 respectively.

[0235] (26) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:261, 262 and 263 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:266, 267 and 268 respectively.

[0236] (27) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:271, 272 and 273 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:276, 277 and 278 respectively;

[0237] (28) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:281, 282 and 283 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:286, 287 and 288 respectively;

[0238] (29) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:291, 292 and 293 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:296, 297 and 298 respectively;

[0239] (30) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:311, 312 and 313 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:316, 317 and 318 respectively.

[0240] (31) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:321, 322 and 323 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:326, 327 and 328 respectively;

[0241] (32) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:331, 332 and 333 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:336, 337 and 338 respectively;

[0242] (33) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:341, 342 and 343 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:346, 347 and 348 respectively.

[0243] (34) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:351, 352 and 353 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:356, 357 and 358 respectively.

[0244] (35) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:361, 362 and 363 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:366, 367 and 368 respectively.

[0245] (36) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:371, 372 and 373 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:376, 377 and 378 respectively.

[0246] (37) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:381, 382 and 383 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:386, 387 and 388 respectively.

[0247] (38) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:391, 392 and 393 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:396, 397 and 398 respectively.

[0248] (39) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:401, 402 and 403 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:406, 407 and 408 respectively.

[0249] (40) The VH comprises HCDR1, HCDR2, and HCDR3 having amino acid sequences as shown in SEQ ID NO:411, 412, and 413, respectively; and the VL comprises LCDR1, LCDR2, and LCDR3 having amino acid sequences as shown in SEQ ID NO:416, 417, and 418, respectively; or

[0250] (41) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:481, 482 and 483 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:486, 487 and 488 respectively.

[0251] In some embodiments, the present invention provides an anti-CD200R1 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

[0252] (1) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:300; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:305;

[0253] (2) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:420; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:425;

[0254] (3) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:430; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:435;

[0255] (4) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:440; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:445;

[0256] (5) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:450; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:455;

[0257] (6) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:460; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:465;

[0258] (7) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:30; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:35;

[0259] (8) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:40; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:45;

[0260] (9) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:50; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:55;

[0261] (10) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:60; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:65;

[0262] (11) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:70; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:75;

[0263] (12) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:80; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:85;

[0264] (13) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:90; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:95;

[0265] (14) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:100; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:105;

[0266] (15) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:110; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:115;

[0267] (16) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:120; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:125;

[0268] (17) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:130; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:135;

[0269] (18) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:140; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:145;

[0270] (19) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:150; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:155;

[0271] (20) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:160; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:165;

[0272] (21) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:170; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:175;

[0273] (22) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:180; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:185;

[0274] (23) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:190; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:195;

[0275] (24) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:200; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:205;

[0276] (25) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:210; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:215;

[0277] (26) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:220; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:225;

[0278] (27) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:230; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:235;

[0279] (28) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:240; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:245;

[0280] (29) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:250; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:255;

[0281] (30) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:260; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:265;

[0282] (31) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:270; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:275;

[0283] (32) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:280; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:285;

[0284] (33) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:290; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:295;

[0285] (34) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:310; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:315;

[0286] (35) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:320; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:325;

[0287] (36) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:330; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:335;

[0288] (37) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:340; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:345;

[0289] (38) The VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:350; and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:355;

[0290] (39) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:360; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:365;

[0291] (40) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:370; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:375;

[0292] (41) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:380; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:385;

[0293] (42) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:390; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:395;

[0294] (43) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:400; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:405;

[0295] (44) The VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:410; and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:415; or

[0296] (45) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:480; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:485.

[0297] In some embodiments, VH comprises a functional variant formed by inserting, deleting, and / or substituting one or more amino acids in the amino acid sequence disclosed herein, provided that the functional variant retains the ability to bind CD200R1. In some embodiments, VL comprises a functional variant formed by inserting, deleting, and / or substituting one or more amino acids in the amino acid sequence disclosed herein, provided that the functional variant retains the ability to bind CD200R1.

[0298] The functional variant comprises or consists of an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity with the parent polypeptide.

[0299] In the context of functional variants, the number of inserted, deleted, and / or substituted amino acids preferably does not exceed 40% of the total number of amino acids in the parental amino acid sequence, more preferably not more than 35%, more preferably 1% to 33%, and even more preferably 5% to 30%, more preferably 10% to 25%, and even more preferably 15% to 20%. For example, the number of inserted, deleted, and / or substituted amino acids can be 1 to 20, preferably 1 to 10, more preferably 1 to 7, even more preferably 1 to 5, and most preferably 1 to 2. In preferred embodiments, the number of inserted, deleted, and / or substituted amino acids is 1, 2, 3, 4, 5, 6, or 7.

[0300] In some implementations, insertions, deletions, and / or substitutions can be performed in frame (FR) regions, such as FR1, FR2, FR3, and / or FR4.

[0301] In some embodiments, the substitution of one or more amino acids may be a conservative substitution of one or more amino acids. Such a conservative substitution is preferably a substitution in which one amino acid from the following groups (a) to (e) is replaced by another amino acid residue from the same group: (a) small aliphatic, nonpolar, or weakly polar residues: Ala, Ser, Thr, Pro, and Gly; (b) polar, negatively charged residues and their (uncharged) amides: Asp, Asn, Glu, and Gln; (c) polar, positively charged residues: His, Arg, and Lys; (d) large aliphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and (e) aromatic residues: Phe, Tyr, and Trp.

[0302] The particularly preferred conservative substitutions are as follows: Ala to Gly or to Ser; Arg to Lys; Asn to Gln or to His; Asp to Glu; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or to Pro; His to Asn or to Gln; Ile to Leu or to Val; Leu to Ile or to Val; Lys to Arg, to Gln or to Glu; Met to Leu, to Tyr or to Ile; Phe to Met, to Leu or to Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp; and / or Phe to Val, to Ile or to Leu.

[0303] In some preferred embodiments, the antibody or its antigen fragment comprises VH and VL, wherein:

[0304] (1) The VH contains the amino acid sequence of SEQ ID NO:300; and the VL contains the amino acid sequence of SEQ ID NO:305;

[0305] (2) The VH contains the amino acid sequence of SEQ ID NO:420; and the VL contains the amino acid sequence of SEQ ID NO:425;

[0306] (3) The VH contains the amino acid sequence of SEQ ID NO:430; and the VL contains the amino acid sequence of SEQ ID NO:435;

[0307] (4) The VH contains the amino acid sequence of SEQ ID NO:440; and the VL contains the amino acid sequence of SEQ ID NO:445;

[0308] (5) The VH contains the amino acid sequence of SEQ ID NO:450; and the VL contains the amino acid sequence of SEQ ID NO:455;

[0309] (6) The VH contains the amino acid sequence of SEQ ID NO:460; and the VL contains the amino acid sequence of SEQ ID NO:465;

[0310] (7) The VH contains the amino acid sequence of SEQ ID NO:30; and the VL contains the amino acid sequence of SEQ ID NO:35;

[0311] (8) The VH contains the amino acid sequence of SEQ ID NO:40; and the VL contains the amino acid sequence of SEQ ID NO:45;

[0312] (9) The VH contains the amino acid sequence of SEQ ID NO:50; and the VL contains the amino acid sequence of SEQ ID NO:55;

[0313] (10) The VH contains the amino acid sequence of SEQ ID NO:60; and the VL contains the amino acid sequence of SEQ ID NO:65;

[0314] (11) The VH contains the amino acid sequence of SEQ ID NO:70; and the VL contains the amino acid sequence of SEQ ID NO:75;

[0315] (12) The VH contains the amino acid sequence of SEQ ID NO:80; and the VL contains the amino acid sequence of SEQ ID NO:85;

[0316] (13) The VH contains the amino acid sequence of SEQ ID NO:90; and the VL contains the amino acid sequence of SEQ ID NO:95;

[0317] (14) The VH contains the amino acid sequence of SEQ ID NO:100; and the VL contains the amino acid sequence of SEQ ID NO:105;

[0318] (15) The VH contains the amino acid sequence of SEQ ID NO:110; and the VL contains the amino acid sequence of SEQ ID NO:115;

[0319] (16) The VH contains the amino acid sequence of SEQ ID NO:120; and the VL contains the amino acid sequence of SEQ ID NO:125;

[0320] (17) The VH contains the amino acid sequence of SEQ ID NO:130; and the VL contains the amino acid sequence of SEQ ID NO:135;

[0321] (18) The VH contains the amino acid sequence of SEQ ID NO:140; and the VL contains the amino acid sequence of SEQ ID NO:145;

[0322] (19) The VH contains the amino acid sequence of SEQ ID NO:150; and the VL contains the amino acid sequence of SEQ ID NO:155;

[0323] (20) The VH contains the amino acid sequence of SEQ ID NO:160; and the VL contains the amino acid sequence of SEQ ID NO:165;

[0324] (21) The VH contains the amino acid sequence of SEQ ID NO:170; and the VL contains the amino acid sequence of SEQ ID NO:175;

[0325] (22) The VH contains the amino acid sequence of SEQ ID NO:180; and the VL contains the amino acid sequence of SEQ ID NO:185;

[0326] (23) The VH contains the amino acid sequence of SEQ ID NO:190; and the VL contains the amino acid sequence of SEQ ID NO:195;

[0327] (24) The VH contains the amino acid sequence of SEQ ID NO:200; and the VL contains the amino acid sequence of SEQ ID NO:205;

[0328] (25) The VH contains the amino acid sequence of SEQ ID NO:210; and the VL contains the amino acid sequence of SEQ ID NO:215;

[0329] (26) The VH contains the amino acid sequence of SEQ ID NO:220; and the VL contains the amino acid sequence of SEQ ID NO:225;

[0330] (27) The VH contains the amino acid sequence of SEQ ID NO:230; and the VL contains the amino acid sequence of SEQ ID NO:235;

[0331] (28) The VH contains the amino acid sequence of SEQ ID NO:240; and the VL contains the amino acid sequence of SEQ ID NO:245;

[0332] (29) The VH contains the amino acid sequence of SEQ ID NO:250; and the VL contains the amino acid sequence of SEQ ID NO:255;

[0333] (30) The VH contains the amino acid sequence of SEQ ID NO:260; and the VL contains the amino acid sequence of SEQ ID NO:265;

[0334] (31) The VH contains the amino acid sequence of SEQ ID NO:270; and the VL contains the amino acid sequence of SEQ ID NO:275;

[0335] (32) The VH contains the amino acid sequence of SEQ ID NO:280; and the VL contains the amino acid sequence of SEQ ID NO:285;

[0336] (33) The VH contains the amino acid sequence of SEQ ID NO:290; and the VL contains the amino acid sequence of SEQ ID NO:295;

[0337] (34) The VH contains the amino acid sequence of SEQ ID NO:310; and the VL contains the amino acid sequence of SEQ ID NO:315;

[0338] (35) The VH contains the amino acid sequence of SEQ ID NO:320; and the VL contains the amino acid sequence of SEQ ID NO:325;

[0339] (36) The VH contains the amino acid sequence of SEQ ID NO:330; and the VL contains the amino acid sequence of SEQ ID NO:335;

[0340] (37) The VH contains the amino acid sequence of SEQ ID NO:340; and the VL contains the amino acid sequence of SEQ ID NO:345;

[0341] (38) The VH contains the amino acid sequence of SEQ ID NO:350; and the VL contains the amino acid sequence of SEQ ID NO:355;

[0342] (39) The VH contains the amino acid sequence of SEQ ID NO:360; and the VL contains the amino acid sequence of SEQ ID NO:365;

[0343] (40) The VH contains the amino acid sequence of SEQ ID NO:370; and the VL contains the amino acid sequence of SEQ ID NO:375;

[0344] (41) The VH contains the amino acid sequence of SEQ ID NO:380; and the VL contains the amino acid sequence of SEQ ID NO:385;

[0345] (42) The VH contains the amino acid sequence of SEQ ID NO:390; and the VL contains the amino acid sequence of SEQ ID NO:395;

[0346] (43) The VH contains the amino acid sequence of SEQ ID NO:400; and the VL contains the amino acid sequence of SEQ ID NO:405; or

[0347] (44) The VH contains the amino acid sequence of SEQ ID NO:410; and the VL contains the amino acid sequence of SEQ ID NO:415; or

[0348] (45) The VH contains the amino acid sequence of SEQ ID NO:480; and the VL contains the amino acid sequence of SEQ ID NO:485.

[0349] In some embodiments, the antibodies provided by the present invention are mouse antibodies, chimeric antibodies, or humanized antibodies.

[0350] Based on the amino acid sequence of the constant region of the antibody heavy chain, immunoglobulin molecules can be classified into five classes (isotypes): IgA, IgD, IgE, IgG, and IgM, and can be further divided into different subtypes, such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. Based on the amino acid sequence of the light chain, the antibody light chain can be divided into lambda (λ) chains and kappa (κ) chains. The antibodies disclosed herein can be any of the above classes or subtypes.

[0351] The antibodies disclosed herein can be complete antibodies or antigen-binding fragments thereof. An antigen-binding fragment can be any fragment of an antibody that retains the ability to specifically bind to CD200R1. Examples of antigen-binding fragments include, but are not limited to: Fab fragments; F(ab')2 fragments; Fab' fragments; Fd fragments; Fd' fragments; Fv fragments; scFv fragments; dAb fragments; individual complementarity-determining regions (CDRs); nanobodies; linear antibodies consisting of a pair of tandem Fd fragments (VH-CH1-VH-CH1); and modified forms of any of the aforementioned fragments that retain antigen-binding activity.

[0352] In some embodiments, the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fv, scFv, and ds-scFv. In a preferred embodiment, the antigen-binding fragment is Fab. In another preferred embodiment, the antigen-binding fragment is Fv. In yet another preferred embodiment, the antigen-binding fragment is scFv.

[0353] In some implementations, the antibody is a monovalent, bivalent, or multivalent antibody.

[0354] In some implementations, the antibody is a monoclonal antibody, a bispecific antibody, or a multispecific antibody.

[0355] In some embodiments, the antibody is a bispecific antibody. A bispecific antibody comprises an antibody or antigen-binding fragment thereof that binds to CD200R1 as described herein, and a second antigen-binding domain that binds to a second antigen. The second antigen may be selected from tumor-associated antigens, pro-inflammatory cytokines, immune cell antigens, and immune checkpoint molecules.

[0356] In some embodiments, the antibody of the present invention may comprise an Fc region. The Fc region may be any isotype, including but not limited to IgG1, IgG2, IgG3, and IgG4, and may contain one or more mutations or modifications. In one embodiment, the Fc region is an IgG1 isotype or derived therefrom, optionally having one or more mutations or modifications. In one embodiment, the Fc region is human IgG Fc. In one embodiment, the Fc region is human IgG1 Fc. In one embodiment, the Fc region is human IgG4 Fc, such as S228P mutant IgG4 (Eu number). In one embodiment, the Fc region is mouse IgG Fc. In one embodiment, the Fc region is mouse IgG1 Fc. In one embodiment, the Fc region is mouse IgG2a Fc. In one embodiment, the Fc region is mouse IgG2b Fc. In one embodiment, the Fc region is mouse IgG2c Fc. In one embodiment, the Fc region is mouse IgG3 Fc. In a preferred embodiment, the Fc region is human IgG1 Fc.

[0357] In one implementation, the Fc region is an S228P mutant IgG4 (Eu number), which, compared to wild-type IgG4, has an S228P substitution in the hinge region, which helps prevent Fab arm exchange and has improved stability.

[0358] In one embodiment, the Fc region has reduced effector function, such as reduced binding to ADCC, ADCP, CDC and / or Clq, FcγRI, FcγRII, or FcγRIIIA. For example, the Fc region may be an IgG1 isotype or a non-IgG1 type, such as IgG2, IgG3, or IgG4, which has been mutated to reduce or even eliminate its ability to mediate effector function. For example, compared to the wild-type human IgG1 sequence, the Fc region may contain an amino acid sequence with one or more of the following amino acid substitutions: E233P, L234A, L234F, L235A, L235E, G237A, N297A, N297D, P331S, and P329G. In a preferred embodiment, the Fc region contains L234A and L235A (LA mutation).

[0359] In other embodiments, the Fc region has an extended serum half-life. Examples of altering (e.g., decreasing or increasing) the in vivo half-life of an antibody can be found, for example, International Publications WO 02 / 060919, WO 98 / 23289, and WO 97 / 34631; and U.S. Patents 5,869,046, 6,121,022, 6,277,375, and 6,165,745, all of which are incorporated herein by reference in their entirety. In some embodiments, one, two, or more amino acid mutations (e.g., substitution, deletion, or insertion) are introduced into the constant domain of IgG or its FcRn binding fragment (preferably the Fc or hinge-Fc domain fragment) to reduce the in vivo half-life of the antibody. In other embodiments, one, two, or more amino acid mutations (e.g., substitutions, deletions, or insertions) are introduced into the constant domain of IgG or its FcRn binding fragment (preferably an Fc or hinge-Fc domain fragment) to increase the in vivo half-life of the antibody. In one specific embodiment, the antibody may have one or more amino acid mutations (e.g., substitutions) (according to EU numbering system) in the second constant (CH2) domain (residues 231-340 of human IgG1) and / or the third constant (CH3) domain (residues 341-447 of human IgG1). In one specific embodiment, the constant region of the antibody IgG1 described herein includes a substitution of methionine (M) at position 252 to tyrosine (Y), a substitution of serine (S) at position 254 to threonine (T), and a substitution of threonine (T) at position 256 to glutamate (E) (according to EU numbering system). See U.S. Patent No. 7,658,921, which is incorporated herein by reference in its entirety. It has been shown that the half-life of such mutant IgG (referred to as the "YTE mutant") is four times longer than that of the wild-type form of the same antibody (see Dall Acqua WF et al. (2006) J Biol Chem 281:23514-24, which is incorporated herein by reference in its entirety). In a preferred embodiment, the Fc region comprises M252Y, S254T, and T256E (YTE mutant).

[0360] In one embodiment, the Fc region of the present invention includes a conservative substitution, such as K214R.

[0361] In some embodiments, the antibody provided by the present invention comprises a heavy chain (HC) and a light chain (LC), wherein:

[0362] (1) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:304; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:309;

[0363] (2) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:424; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:429;

[0364] (3) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:434; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:439;

[0365] (4) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:444; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:449;

[0366] (5) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:454; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:459;

[0367] (6) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:464; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:469;

[0368] (7) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:34; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:39;

[0369] (8) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:44; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:49;

[0370] (9) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:54; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:59;

[0371] (10) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:64; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:69;

[0372] (11) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:74; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:79;

[0373] (12) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:84; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:89;

[0374] (13) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:94; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:99;

[0375] (14) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:104; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:109;

[0376] (15) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:114; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:119;

[0377] (16) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:124; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:129;

[0378] (17) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:134; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:139;

[0379] (18) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:144; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:149;

[0380] (19) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:154; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:159;

[0381] (20) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:164; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:169;

[0382] (21) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:174; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:179;

[0383] (22) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:184; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:189;

[0384] (23) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:194; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:199;

[0385] (24) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:204; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:209;

[0386] (25) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:214; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:219;

[0387] (26) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:224; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:229;

[0388] (27) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:234; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:239;

[0389] (28) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:244; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:249;

[0390] (29) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:254; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:259;

[0391] (30) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:264; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:269;

[0392] (31) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:274; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:279;

[0393] (32) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:284; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:289;

[0394] (33) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:294; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:299;

[0395] (34) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:314; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:319;

[0396] (35) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:324; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:329;

[0397] (36) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:334; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:339;

[0398] (37) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:344; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:349;

[0399] (38) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:354; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:359;

[0400] (39) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:364; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:369;

[0401] (40) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:374; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:379;

[0402] (41) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:384; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:389;

[0403] (42) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:394; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:399;

[0404] (43) The HC contains an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:404; and the LC contains an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:409; or

[0405] (44) The HC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:414; and the LC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:419; or

[0406] (45) The HC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:484; and the LC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:489.

[0407] In some embodiments, the antibody provided by the present invention comprises a heavy chain (HC) and a light chain (LC), wherein:

[0408] (1) The HC contains the amino acid sequence of SEQ ID NO:304; and the LC contains the amino acid sequence of SEQ ID NO:309;

[0409] (2) The HC contains the amino acid sequence of SEQ ID NO:424; and the LC contains the amino acid sequence of SEQ ID NO:429;

[0410] (3) The HC contains the amino acid sequence of SEQ ID NO:434; and the LC contains the amino acid sequence of SEQ ID NO:439;

[0411] (4) The HC contains the amino acid sequence of SEQ ID NO:444; and the LC contains the amino acid sequence of SEQ ID NO:449;

[0412] (5) The HC contains the amino acid sequence of SEQ ID NO:454; and the LC contains the amino acid sequence of SEQ ID NO:459;

[0413] (6) The HC contains the amino acid sequence of SEQ ID NO:464; and the LC contains the amino acid sequence of SEQ ID NO:469;

[0414] (7) The HC contains the amino acid sequence of SEQ ID NO:34; and the LC contains the amino acid sequence of SEQ ID NO:39;

[0415] (8) The HC contains the amino acid sequence of SEQ ID NO:44; and the LC contains the amino acid sequence of SEQ ID NO:49;

[0416] (9) The HC contains the amino acid sequence of SEQ ID NO:54; and the LC contains the amino acid sequence of SEQ ID NO:59;

[0417] (10) The HC contains the amino acid sequence of SEQ ID NO:64; and the LC contains the amino acid sequence of SEQ ID NO:69;

[0418] (11) The HC contains the amino acid sequence of SEQ ID NO:74; and the LC contains the amino acid sequence of SEQ ID NO:79;

[0419] (12) The HC contains the amino acid sequence of SEQ ID NO:84; and the LC contains the amino acid sequence of SEQ ID NO:89;

[0420] (13) The HC contains the amino acid sequence of SEQ ID NO:94; and the LC contains the amino acid sequence of SEQ ID NO:99;

[0421] (14) The HC contains the amino acid sequence of SEQ ID NO:104; and the LC contains the amino acid sequence of SEQ ID NO:109;

[0422] (15) The HC contains the amino acid sequence of SEQ ID NO:114; and the LC contains the amino acid sequence of SEQ ID NO:119;

[0423] (16) The HC contains the amino acid sequence of SEQ ID NO:124; and the LC contains the amino acid sequence of SEQ ID NO:129;

[0424] (17) The HC contains the amino acid sequence of SEQ ID NO:134; and the LC contains the amino acid sequence of SEQ ID NO:139;

[0425] (18) The HC contains the amino acid sequence of SEQ ID NO:144; and the LC contains the amino acid sequence of SEQ ID NO:149;

[0426] (19) The HC contains the amino acid sequence of SEQ ID NO:154; and the LC contains the amino acid sequence of SEQ ID NO:159;

[0427] (20) The HC contains the amino acid sequence of SEQ ID NO:164; and the LC contains the amino acid sequence of SEQ ID NO:169;

[0428] (21) The HC contains the amino acid sequence of SEQ ID NO:174; and the LC contains the amino acid sequence of SEQ ID NO:179;

[0429] (22) The HC contains the amino acid sequence of SEQ ID NO:184; and the LC contains the amino acid sequence of SEQ ID NO:189;

[0430] (23) The HC contains the amino acid sequence of SEQ ID NO:194; and the LC contains the amino acid sequence of SEQ ID NO:199;

[0431] (24) The HC contains the amino acid sequence of SEQ ID NO:204; and the LC contains the amino acid sequence of SEQ ID NO:209;

[0432] (25) The HC contains the amino acid sequence of SEQ ID NO:214; and the LC contains the amino acid sequence of SEQ ID NO:219;

[0433] (26) The HC contains the amino acid sequence of SEQ ID NO:224; and the LC contains the amino acid sequence of SEQ ID NO:229;

[0434] (27) The HC contains the amino acid sequence of SEQ ID NO:234; and the LC contains the amino acid sequence of SEQ ID NO:239;

[0435] (28) The HC contains the amino acid sequence of SEQ ID NO:244; and the LC contains the amino acid sequence of SEQ ID NO:249;

[0436] (29) The HC contains the amino acid sequence of SEQ ID NO:254; and the LC contains the amino acid sequence of SEQ ID NO:259;

[0437] (30) The HC contains the amino acid sequence of SEQ ID NO:264; and the LC contains the amino acid sequence of SEQ ID NO:269;

[0438] (31) The HC contains the amino acid sequence of SEQ ID NO:274; and the LC contains the amino acid sequence of SEQ ID NO:279;

[0439] (32) The HC contains the amino acid sequence of SEQ ID NO:284; and the LC contains the amino acid sequence of SEQ ID NO:289;

[0440] (33) The HC contains the amino acid sequence of SEQ ID NO:294; and the LC contains the amino acid sequence of SEQ ID NO:299;

[0441] (34) The HC contains the amino acid sequence of SEQ ID NO:314; and the LC contains the amino acid sequence of SEQ ID NO:319;

[0442] (35) The HC contains the amino acid sequence of SEQ ID NO:324; and the LC contains the amino acid sequence of SEQ ID NO:329;

[0443] (36) The HC contains the amino acid sequence of SEQ ID NO:334; and the LC contains the amino acid sequence of SEQ ID NO:339;

[0444] (37) The HC contains the amino acid sequence of SEQ ID NO:344; and the LC contains the amino acid sequence of SEQ ID NO:349;

[0445] (38) The HC contains the amino acid sequence of SEQ ID NO:354; and the LC contains the amino acid sequence of SEQ ID NO:359;

[0446] (39) The HC contains the amino acid sequence of SEQ ID NO:364; and the LC contains the amino acid sequence of SEQ ID NO:369;

[0447] (40) The HC contains the amino acid sequence of SEQ ID NO:374; and the LC contains the amino acid sequence of SEQ ID NO:379;

[0448] (41) The HC contains the amino acid sequence of SEQ ID NO:384; and the LC contains the amino acid sequence of SEQ ID NO:389;

[0449] (42) The HC contains the amino acid sequence of SEQ ID NO:394; and the LC contains the amino acid sequence of SEQ ID NO:399;

[0450] (43) The HC contains the amino acid sequence of SEQ ID NO:404; and the LC contains the amino acid sequence of SEQ ID NO:409; or

[0451] (44) The HC contains the amino acid sequence of SEQ ID NO:414; and the LC contains the amino acid sequence of SEQ ID NO:419; or

[0452] (45) The HC contains the amino acid sequence of SEQ ID NO:484; and the LC contains the amino acid sequence of SEQ ID NO:489.

[0453] Nucleic acid

[0454] This disclosure provides nucleic acids containing nucleotide sequences encoding the anti-CD200R1 antibody or its antigen-binding fragment disclosed herein.

[0455] The term "nucleic acid" includes single-stranded and double-stranded nucleotide polymers. Nucleic acids can be ribonucleotides or deoxyribonucleotides or modified forms of any type of nucleotide. These modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and nucleotide bond modifications such as thiophosphates, dithiophosphates, selenophosphates, diselenophosphates, phenylthiophosphates, aniline phosphates, and aminophosphates.

[0456] For example, the present invention provides nucleic acid molecules encoding any of the heavy chain variable region sequences disclosed herein. The present invention also provides nucleic acid molecules that are at least 90%, at least 95%, at least 98%, or at least 99% identical to the nucleic acid encoding any of the heavy chain variable region sequences disclosed herein.

[0457] For example, the present invention provides a nucleic acid molecule encoding any of the light chain variable region sequences disclosed herein. The present invention also provides a nucleic acid molecule that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the nucleic acid encoding any of the light chain variable region sequences disclosed herein.

[0458] For example, the present invention provides a nucleic acid molecule encoding a heavy chain variable region sequence comprising a CDR sequence of any of the heavy chain variable region sequences disclosed herein. The present invention also provides a nucleic acid molecule encoding a heavy chain variable region sequence comprising a CDR sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to a CDR sequence of any of the heavy chain variable region sequences disclosed herein.

[0459] For example, the present invention provides a nucleic acid molecule encoding a light chain variable region sequence comprising a CDR sequence of any of the light chain variable region sequences disclosed herein. The present invention also provides a nucleic acid molecule encoding a light chain variable region sequence comprising a CDR sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to a CDR sequence of any of the light chain variable region sequences disclosed herein.

[0460] In some embodiments, the nucleic acid is ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). In some embodiments, the present invention provides ribonucleic acid (RNA) comprising a nucleotide sequence encoding an antibody disclosed herein. In some embodiments, the present invention provides deoxyribonucleic acid (DNA) comprising a deoxynucleotide sequence encoding an antibody disclosed herein.

[0461] In some embodiments, deoxyribonucleic acid (DNA) can be introduced into human cells in vivo. In some embodiments, the deoxyribonucleic acid (DNA) of the present invention is contained in a vector or delivery agent. In some embodiments, the deoxyribonucleic acid (DNA) of the present invention is integrated into the genome of a cell.

[0462] In some embodiments, ribonucleic acid (RNA) can be introduced into human cells in vivo. In some embodiments, the ribonucleic acid (RNA) of the present invention is contained in a vector or delivery agent.

[0463] carrier

[0464] This disclosure provides a vector containing the nucleic acid disclosed herein, the nucleic acid containing a nucleotide sequence encoding the anti-CD200R1 antibody disclosed herein or an antigen-binding fragment thereof.

[0465] In some embodiments, the vector is an expression vector capable of expressing a polypeptide containing a variable region of the heavy or light chain of an antibody. For example, the present invention provides an expression vector comprising any of the above-described nucleic acid molecules.

[0466] Any vector may be used in this disclosure. In some embodiments, the vector is a viral vector. In some embodiments, the vector is a retroviral vector, a DNA vector, a murine leukemia virus vector, an SFG vector, a plasmid, an RNA vector, an adenovirus vector, a baculovirus vector, an Epstein-Barr virus vector, a papillomavirus vector, a vaccinia virus vector, a herpes simplex virus vector, an adenovirus-associated vector (AAV), a lentiviral vector, or any combination thereof. Suitable exemplary vectors include, for example, pGAR, pBABE-puro, pBABE-neo largeTcDNA, pBABE-hygro-hTERT, pMKO.1GFP, MSCV-IRES-GFP, pMSCV PIG (Puro IRES GFP empty plasmid), pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE, MSCV IRES luciferase, pMIG, MDH1-PGK-GFP_2.0, TtRMPVIR, pMSCV-IRES-mCherry FP, pRetroX GFP T2A Cre, pRXTN, pLncEXP, and pLXIN-Luc.

[0467] The expression vector can be any suitable recombinant expression vector. Suitable vectors include those designed for propagation and amplification or for expression, or both, such as plasmids and viruses. For example, vectors can be selected from the pUC series (Fermentas Life Sciences, Glen Burnie, Md.), pBluescript series (Stratagene, LaJolla, Calif.), pET series (Novagen, Madison, Wis.), pGEX series (Pharmacia Biotech, Uppsala, Sweden), and pEX series (Clontech, Palo Alto, Calif.). Phage vectors such as λGT10, λGT11, λZapII (Stratagene), λEMBL4, and λNM1149 can also be used. Examples of plant expression vectors that can be used in this disclosure include pBI01, pBI101.2, pBI101.3, pBI121, and pBIN19 (Clontech). Examples of animal expression vectors that can be used in this disclosure include pcDNA, pEUK-Cl, pMAM, and pMAMneo (Clontech).

[0468] Recombinant expression vectors can be prepared using standard recombinant DNA techniques described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Press, Cold Spring Harbor, NY 2001; and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, NY, 1994. Circular or linear expression vector constructs can be prepared to contain the functionality of the replication system in prokaryotic or eukaryotic host cells. The replication system can be derived from, for example, COLEL, 2μ plasmid, λ, SV40, bovine papillomavirus, etc.

[0469] For example, the vector could be an adenoviral vector containing a nucleotide sequence encoding an antibody disclosed herein. The vector could be administered to a subject, then enter the subject's cells, thereby integrating the nucleotide sequence encoding the antibody disclosed herein into the cell's genome, and subsequently the cells express the antibody disclosed herein.

[0470] host cells

[0471] This disclosure provides host cells containing the nucleic acids or vectors disclosed herein.

[0472] Any cell can be used as the host cell for the nucleic acids or vectors disclosed herein. In some embodiments, the cell may be a prokaryotic cell, fungal cell, yeast cell, or higher eukaryotic cell such as a mammalian cell. Suitable prokaryotic cells include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, such as Enterobacteriaceae, such as Escherichia, for example, E. coli; Enterobacter; Erwinia; Klebsiella; Proteus; Salmonella, for example, Salmonella typhimurium; Serratia, for example, Serratia marcescens. The bacteria include *Bacillus subtilis* and *Shigella*; *Bacillus* species, such as *B. subtilis* and *B. licheniformis*; *Pseudomonas* species, such as *P. aeruginosa*; and *Streptomyces*. In some embodiments, the cells are human cells. In some embodiments, the cells are immune cells. In some embodiments, the host cells include, for example, CHO cells, such as CHOS cells and CHO-K1 cells, or HEK293 cells, such as HEK293A, HEK293T, and HEK293FS.

[0473] The host cells of the present invention are prepared by introducing the vectors or nucleic acids disclosed herein in vitro or ex vivo. The host cells of the present invention can be administered to a subject, and the host cells express the antibodies disclosed herein in vivo.

[0474] This invention provides host cells in which any of the above-described vectors have been introduced. This invention also provides a method for preparing the antibodies of this invention, the method comprising a) culturing the host cells of this invention under conditions suitable for antibody production; and b) obtaining the antibodies from the culture.

[0475] Pharmaceutical Composition

[0476] This disclosure provides pharmaceutical compositions comprising the antibodies or antigen-binding fragments thereof disclosed herein, the nucleic acid molecules disclosed herein, the carriers disclosed herein, the cells disclosed herein, and / or the conjugates disclosed herein, and optionally pharmaceutically acceptable carriers or excipients.

[0477] The antibodies or antigen-binding fragments or agents thereof (also referred to herein as “active compounds”) of the present invention, and their derivatives, fragments, analogs, and homologues, may be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise antibodies or antigen-binding fragments or agents thereof, along with a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delay agents compatible with drug administration. Preferred examples of such carriers or excipients include, but are not limited to, water, saline, Ringer's solution, dextran solution, and 5% human serum albumin. Liposomes and non-aqueous media such as non-volatile oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agent is incompatible with the active compound, its use in the composition is contemplated. Additional active compounds may also be incorporated into the composition. Pharmaceutical compositions of this application may also contain more than one active compound, typically those with complementary activities that do not adversely affect each other. The type and effective dose of such drugs depend on factors such as the amount and type of antagonist present in the formulation, as well as the clinical parameters of the subject.

[0478] In some embodiments of the pharmaceutical compositions disclosed herein, the pharmaceutical composition further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from antibodies, chemotherapeutic agents, siRNA, antisense oligonucleotides, peptides, and small molecule drugs.

[0479] The pharmaceutical compositions of the present invention can be formulated to be compatible with their intended routes of administration. Examples of routes of administration include parenteral administration, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), mucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous application may include the following components: sterile diluents, such as water for injection, saline solution, non-volatile oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as tetraethylamine oxalate (EDTA); buffers, such as acetate, citrate, or phosphate; and agents for adjusting tension, such as sodium chloride or dextran. The pH value can be adjusted with an acid or base, such as hydrochloric acid or sodium hydroxide. Parenteral formulations may be packaged in ampoules, disposable syringes, or multi-dose vials made of glass or plastic.

[0480] Pharmaceutical compositions suitable for injectable applications include sterile aqueous solutions (if water-soluble) or dispersions and sterile powders for the ad hoc preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, antibacterial water, Cremophor EL... TM(BASF, Parsippany, NJ) or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and should be a fluid present in a manner easily injectable. It must be stable under preparation and storage conditions and must be protected against contamination by microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Appropriate flowability can be maintained, for example, by using coatings such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using surfactants. The action of microorganisms can be prevented by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferable to include isotonic agents in the composition, such as sugars, polyols such as mannitol, sorbitol, and sodium chloride. The absorption of injectable compositions can be prolonged by including agents that delay absorption, such as aluminum monostearate and gelatin.

[0481] Sterile injectable solutions can be prepared by incorporating the desired amount of the active compound with one or a combination of the ingredients listed above (as needed) into a suitable solvent, followed by filtration and sterilization. Typically, dispersions are prepared by introducing the active compound into a sterile medium containing a basic dispersion medium and other desired ingredients from those listed above. In the case of sterile powders used to prepare sterile injectable solutions, the preparation method is vacuum drying and freeze-drying to produce a powder of the active ingredient plus any other desired ingredients from its previously sterile filtered solution.

[0482] Oral compositions typically include an inert diluent or an edible carrier. They may be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound may be mixed with excipients and administered in the form of tablets, lozenges, or capsules. Oral compositions may also be prepared using a fluid carrier used as a mouthwash, wherein the compound in the fluid carrier is administered orally and rinsed and spat out or swallowed. Pharmaceutically compatible binding agents and / or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc., may contain any of the following ingredients or compounds of similar nature: binding agents, such as microcrystalline cellulose, astragalus gum, or gelatin; excipients, such as starch or lactose; disintegrants, such as alginate, Primogel, or corn starch; lubricants, such as magnesium stearate or sterotes; gliding agents, such as colloidal silica; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint oil, methyl salicylate, or orange flavoring.

[0483] For inhalation administration, the compound is delivered as an aerosol spray from a pressure vessel or dispenser or sprayer containing a suitable propellant (e.g., a gas such as carbon dioxide).

[0484] Systemic application can also be performed via transmucosal or transdermal routes. For transmucosal or transdermal application, a penetrant suitable for the target penetration barrier is used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives used for transmucosal application. Transmucosal application can be accomplished using nasal sprays or suppositories. For transdermal application, the active compound is formulated as an ointment, cream, gel, or lotion known in the art.

[0485] Active compounds can also be formulated as suppositories (e.g., using conventional suppository bases such as cocoa butter and other glycerides) or as retention enemas for rectal delivery.

[0486] In one embodiment, the active compound is prepared together with a carrier (such as a controlled-release formulation, including implants and microencapsulated delivery systems) that protects the compound from rapid elimination from the body. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art.

[0487] This invention provides therapeutic compositions comprising the antibody or antigen-binding fragment thereof of the invention. The therapeutic compositions according to the invention will be administered together with suitable carriers, excipients, and other pharmaceutical agents incorporated into the formulation to provide improved transfer, delivery, tolerability, etc. Many suitable formulations are available in formulations known to all medicinal chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, vesicle-containing lipids (cationic or anionic) (such as LIPOFECTIN). TM DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, polyethylene glycol emulsions (polyethylene glycol of various molecular weights), semi-solid gels, and semi-solid mixtures containing polyethylene glycol. See also Powell et al., "Compendium of excipients for parenteral formulations," PDA (1998), J Pharm Sci Technol 52:238-311.

[0488] Conjugate

[0489] This disclosure provides conjugates comprising the antibody or antigen-binding fragment thereof disclosed herein, and the chemical portion conjugated thereto.

[0490] In the context of this disclosure, a “conjugate” is an antibody or antibody fragment (such as an antigen-binding fragment) covalently linked to a chemical moiety. The chemical moiety can be, for example, a drug, toxin, therapeutic agent, detectable marker, protein, nucleic acid, lipid, nanoparticle, carbohydrate, or recombinant virus. Antibody conjugates are commonly referred to as “immunoconjugates.” When a conjugate contains an antibody linked to a drug (e.g., a cytotoxic agent), the conjugate is commonly referred to as an “antibody-drug conjugate” or “ADC.”

[0491] The terms "conjugation" or "linkage" can refer to the process by which two polypeptides become a single, continuous polypeptide molecule. In one embodiment, an antibody is linked to a chemical moiety. In another embodiment, the antibody linked to the chemical moiety is further linked to a lipid or other molecule to a protein or peptide to increase its half-life in vivo. Linkage can be performed chemically or recombinantly. In one embodiment, the linking is chemical, wherein a reaction between the antibody moiety and the chemical moiety produces a covalent bond formed between the two molecules to form a single molecule. A peptide linker (short peptide sequence) may optionally be included between the antibody and the chemical moiety.

[0492] The chemical moiety can be attached to the antibody of the present invention using any number of methods known to those skilled in the art. Covalent and non-covalent attachment methods can be used. The procedure for attaching the chemical moiety to the antibody varies depending on the chemical structure of the chemical moiety. Peptides typically contain multiple functional groups; such as carboxylic acid (COOH), free amine (-NH2), or thiol (-SH) moieties, which can be used to react with suitable functional groups on the antibody to result in the binding of the chemical moiety. Alternatively, the antibody is derivatized to expose or attach additional reactive functional groups. Derivatization can involve attaching any of a number of known linker molecules. The linker can be any molecule used to attach the antibody to the chemical moiety. The linker is capable of forming a covalent bond with both the antibody and the chemical moiety. Suitable linkers are well known to those skilled in the art and include, but are not limited to, straight-chain or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. In the case where the antibody and chemical moiety are peptides, the linker can be attached via their side groups to the constituent amino acids (e.g., via disulfide bonds to cysteine) or to the α-carbon amino and carboxyl groups of the terminal amino acid.

[0493] In some cases, when an immunoconjugate reaches its target site, it is desirable to release a chemical moiety from the antibody. Therefore, in these cases, the immunoconjugate will contain a cleavable linker near the target site.

[0494] Conditions experienced by enzymatically active or immunoconjugates within or near target cells may induce linker cleavage to release the chemical portion from the antibody.

[0495] Given the numerous methods reported for attaching various radiodiagnostic compounds, radiotherapy compounds, markers (such as enzymes or fluorescent molecules), drugs, toxins, and other agents to antibodies, those skilled in the art will be able to determine a suitable method for attaching a given agent to an antibody or other peptide.

[0496] The antibodies disclosed herein can be derivatized or linked to another molecule (such as another peptide or protein). Typically, antibodies or portions thereof are derivatized so that binding to the target antigen is not adversely affected by derivatization or labeling. For example, antibodies can be functionally linked (through chemical coupling, gene fusion, non-covalent association, or other means) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a divalent antibody), a detection agent, a pharmaceutical agent, and / or a protein or peptide that can mediate association between the antibody or an antibody portion and another molecule (such as the streptavidin core region or a multihistidine tag).

[0497] One type of derivatized antibody is produced by crosslinking two or more antibodies (of the same or different types). Suitable crosslinking agents include heterobifunctional crosslinkers (e.g., m-maleimide benzoyl-N-hydroxysuccinimide ester) or homobifunctional crosslinkers (e.g., disuccinimide octanoate ester) having two distinct reactive moieties separated by a suitable spacer. Such linkers are commercially available.

[0498] In some embodiments of the conjugates disclosed in this invention, the chemical portion is selected from therapeutic agents, detectable portions, and immunostimulatory molecules.

[0499] In some embodiments, the therapeutic agent includes, but is not limited to, immunomodulators, radioactive compounds, enzymes (e.g., perforin), chemotherapeutic agents (e.g., cisplatin), or toxins. In some embodiments, the therapeutic agent may be, for example, maytansine, galdromycin, microtubule inhibitors such as microtubule binding agents (e.g., olistatins), or minor groove binding agents such as galicarmycin.

[0500] Other suitable therapeutic agents include, for example, small molecule cytotoxic agents, which are compounds with a molecular weight of less than 700 Daltons capable of killing mammalian cells. These compounds may also contain toxic metals capable of cytotoxic effects. Furthermore, it should be understood that these small molecule cytotoxic agents also include drug prodrugs, which are compounds that decompose or transform under physiological conditions to release the cytotoxic agent. Examples of such agents include cisplatin, maytansine derivatives, lactammycin, calcitrinin, docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodium photosensitizer II, temozolomide, topotecan, metformin, olritamine E, vincristine, and doxorubicin; peptide cytotoxins, which are proteins or fragments thereof capable of killing mammalian cells, such as ricin, diphtheria toxin, Pseudomonas exotoxin A, DNases, and RNases; radionuclides, which are unstable isotopes of elements that decay with the simultaneous emission of one or more alpha or beta particles or gamma rays, such as iodine-131, rhenium-186, indium-111, yttrium-90, bismuth-210, bismuth-213, actinium-225, and astatine-213; chelating agents can be used to promote the binding of these radionuclides to molecules or polymers thereof.

[0501] In some implementations, the detectable portion may be selected from biotin, streptavidin, enzymes or their catalytically active fragments, radionuclides, nanoparticles, paramagnetic metal ions, or fluorescent, phosphorescent, or chemiluminescent molecules. Detectable portions for diagnostic purposes include, for example, fluorescent labels, radiolabels, enzymes, nucleic acid probes, and contrast agents.

[0502] Antibodies can be conjugated to detectable markers; for example, detectable markers that can be detected by ELISA, spectrophotometry, flow cytometry, microscopy, or diagnostic imaging techniques such as computed tomography (CT), computed axial computed tomography (CAT), magnetic resonance imaging (MRI), nuclear magnetic resonance imaging (NMRI), magnetic resonance tomography (MTR), ultrasound, fiber optic examination, and laparoscopy. Specific, non-limiting examples of detectable markers include fluorophores, chemiluminescent agents, enzyme-linked conjugates, radioisotopes, and heavy metals or compounds (e.g., superparamagnetic iron oxide nanocrystals for MRI detection). For example, useful detectable markers include fluorescent compounds, including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-naphthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors, etc. Bioluminescent markers, such as luciferase, green fluorescent protein (GFP), and yellow fluorescent protein (YFP), can also be used.

[0503] Antibody or antigen-binding fragments can also be conjugated to enzymes that can be used for detection, such as horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase, and glucose oxidase. When an antibody or antigen-binding fragment is conjugated to a detectable enzyme, detection can be achieved by adding additional reagents to generate a recognizable reaction product. For example, in the presence of horseradish peroxidase reagent, the addition of hydrogen peroxide and diaminobenzidine results in a colored reaction product that can be detected visually. Antibody or antigen-binding fragments can also be conjugated to biotin and detected indirectly by binding to avidin or streptavidin. It should be noted that avidin itself can be conjugated to enzymes or fluorescent labels.

[0504] Antibodies can be fused with self-labeled protein tags (e.g., HaloTag). For example, protein tags can be cloned to the ends of constant regions. HaloTag is a self-labeled protein tag derived from bacterial enzymes (haloalkyl dehalogenases) and designed to covalently bind to synthetic ligands. In some cases, the synthetic ligands contain chloroalkane linkers attached to fluorophores such as near-infrared fluorophores (Los et al. (2008) ACS Chem Biol. 3(6):373-82).

[0505] Antibodies can be labeled with magnetic agents such as gadolinium. Antibodies can also be labeled with lanthanides (such as europium and dysprosium) and manganese.

[0506] Paramagnetic particles, such as superparamagnetic iron oxide, can also be used as labels. Antibodies can also be labeled with predetermined polypeptide epitopes recognized by a second reporter gene (such as leucine zipper pairs, binding sites of the second antibody, metal-binding domains, or epitope tags). In some embodiments, the tag is attached by spacer arms of various lengths to reduce potential steric hindrance.

[0507] Antibodies can also be labeled with radioactively labeled amino acids. Radiolabeling can be used for diagnostic and therapeutic purposes. For example, radiolabeling can be used to detect the expression of target antigens by X-rays, emission spectroscopy, or other diagnostic techniques. Examples of peptide labeling include, but are not limited to, the following radioactive isotopes or radioactive nucleotides: 3 H, 14 C 15 N、 35 S, 90 Y、 99 Tc, 111 In、 125 I, 131 I.

[0508] In some implementations, immunostimulatory molecules are immune effector molecules that stimulate an immune response. For example, immunostimulatory molecules can be cytokines such as IL-2 and IFN-γ, chemokines such as IL-8, platelet-4, melanoma growth-stimulating proteins, complement activators; viral / bacterial protein domains, or viral / bacterial peptides.

[0509] Treatment methods and uses

[0510] The present invention provides a method for treating a disease in a subject, comprising administering to the subject an effective amount of an antibody disclosed herein or an antigen-binding fragment thereof, a bispecific antibody disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein, wherein the disease is a CD200R1-mediated disease and / or a disease associated with CD200R1 expression.

[0511] This invention provides the use of the antibodies or antigen-binding fragments thereof disclosed herein, the bispecific antibodies disclosed herein, the conjugates disclosed herein, or the pharmaceutical compositions disclosed herein in the preparation of medicaments for treating CD200R1-mediated diseases and / or diseases associated with CD200R1 expression in subjects.

[0512] The present invention provides antibodies or antigen-binding fragments thereof disclosed herein, bispecific antibodies disclosed herein, conjugates disclosed herein, or pharmaceutical compositions disclosed herein for the treatment of CD200R1-mediated diseases and / or diseases associated with CD200R1 expression in subjects.

[0513] The present invention provides a method for treating a disease in a subject, comprising administering to the subject an effective amount of an antibody disclosed herein or an antigen-binding fragment thereof, a bispecific antibody disclosed herein, a conjugate disclosed herein, or a pharmaceutical composition disclosed herein, wherein the disease is a disease related to interleukin-8 secretion.

[0514] This invention provides the use of the antibodies or antigen-binding fragments thereof disclosed herein, the bispecific antibodies disclosed herein, the conjugates disclosed herein, or the pharmaceutical compositions disclosed herein in the preparation of a medicament for treating a disease associated with interleukin-8 secretion in a subject.

[0515] The present invention provides antibodies or antigen-binding fragments thereof disclosed herein, bispecific antibodies disclosed herein, conjugates disclosed herein, or pharmaceutical compositions disclosed herein for the treatment of diseases associated with interleukin-8 secretion in subjects.

[0516] In some implementations, the disease is selected from inflammatory diseases, autoimmune diseases, allergic diseases, and neurodegenerative diseases.

[0517] In some implementations, the disease is selected from multiple sclerosis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, colitis, atopic dermatitis, and Parkinson's disease.

[0518] In some embodiments, compositions or formulations comprising the anti-CD200R1 antibody of this disclosure may be used to treat conditions or diseases selected from: acne, acute pancreatitis, acute severe ulcerative colitis, adult-onset Still's disease, age-related macular degeneration (AMD), airway hyperresponsiveness, airway inflammation, allergic conjunctivitis, allergic rhinitis, allergic reactions, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), allergic reactions, arthritis pain, asthma, atherosclerosis, colitis, atopic dermatitis, atopic eczema, autoimmune vasculitis, Behcet's disease, cachexia / anorexia, cartilage damage, cerebral ischemia, chronic fatigue syndrome, etc. Chronic obstructive pulmonary disease, Clostridium difficile-associated disease, congestive heart failure, conjunctivitis, coronary artery bypass grafting, coronary restenosis, Crohn's disease, diabetes, diabetic macular edema, diabetic retinopathy, dry eye disease, endometriosis, eosinophilic gastrointestinal disorders, eosinophilic esophagitis, familial influenza autoinflammatory syndrome, familial Mediterranean fever, fever, fibromyalgia, fibrotic diseases, food allergies, generalized pustular psoriasis, glaucoma, glomerulonephritis, gouty arthritis, graft-versus-host disease, helminth infection, hemorrhagic shock, hidradenitis suppurativa, hyperalgesia, hyper-IgD syndrome, hyperuricemia, idiopathic diseases. Pulmonary fibrosis (IPF), infection, inflammatory bowel disease (IBD), inflammatory conditions caused by overuse, inflammatory eye disease associated with corneal transplantation, inflammatory pain, influenza, local ischemia, juvenile arthritis, Kawasaki disease, Leber's congenital amaurosis, Muller-Weiss syndrome, multiple myeloma, multiple sclerosis, musculoskeletal pain, myeloproliferative and other leukemias, myocardial dysfunction, myopathy, nasal polyps, neonatal multisystem inflammatory diseases, neurotoxicity, non-infectious conjunctivitis, orthopedic surgery, osteoarthritis, osteoporosis, pain, palmoplantar pustulosis, Parkinson's disease, periodontitis, peripheral vascular disease, polymyalgia rheumatica, polypoid choroidal vascular disease (PCV) Premature birth, protozoan infection, psoriasis, psoriatic arthritis, pyoderma gangrenosa, reperfusion injury, respiratory syncytial virus (RSV), restenosis, retinal detachment, retinitis pigmentosa, retinopathy of prematurity (ROP), rheumatoid arthritis, septic shock, sickle cell anemia, side effects of radiotherapy, sinusitis, sleep disorders, sprains, Stagger's disease, temporomandibular joint disorder, TNF receptor-related periodic syndrome, transplant rejection, trauma, traumatic eye injury, type 2 diabetes, ulcerative colitis, polyarteritis nodosa, polychondritis polypathiae, gout, cold porphyrin-related periodic syndrome, systemic pustular psoriasis, and uveitis.

[0519] In some implementation methods, the dose administered to the subject may vary depending on the implementation method, the drug used, the method of administration, and the site of treatment and the subject. However, the dose should be sufficient to provide a therapeutic response. Clinicians can determine the effective amount to administer to a person or other subject to treat a medical condition. The precise amount required for effective treatment may depend on many factors, such as antibody activity and the route of administration.

[0520] The dosage of the antibodies, compositions, or conjugates described herein may be administered to mammals in a single dose or in a series of sub-dose over an appropriate period of time, such as daily, bi-weekly, weekly, bi-weekly, bi-weekly, monthly, bi-monthly, semi-annually, or annually as needed. Dosage units containing an effective amount of the antibody, composition, or conjugate may be administered as a single daily dose, or the total daily dose may be administered as needed in two, three, four, or more daily sub-dose units.

[0521] The appropriate route of administration can be chosen by the physician. Administration routes may include parenteral administration, such as by injection, nasal administration, pulmonary administration, or percutaneous administration. Systemic or local administration may be performed via intravenous injection, intramuscular injection, intraperitoneal injection, or subcutaneous injection. In some embodiments, antibodies, compositions, or conjugates are selected for parenteral delivery, inhalation, or delivery via the digestive tract, such as oral administration. The dosage and method of administration can vary depending on the subject's weight, age, condition, etc., and can be appropriately selected.

[0522] The methods and compositions described herein can be used alone or in combination with other therapeutic agents and / or forms. As used herein, the terms “combined” or “in combination” administration should be understood as the delivery of two (or more) different treatments to a subject during the course of the subject’s illness, such that the effects of the treatments on the patient overlap at some point in time. In some embodiments, the delivery of one treatment is still in progress when the second treatment begins, thus creating an overlap in administration. This is sometimes referred to herein as “simultaneous” or “simultaneous delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective due to combined administration. For example, fewer doses of the second treatment may be observed when combined with the first treatment compared to when the second treatment is administered alone without the first treatment, or the second treatment may alleviate symptoms to a greater extent; or a similar situation may exist with the first treatment. In some embodiments, combined administration results in a reduction in symptoms or other parameters related to the illness that is greater than that observed in the absence of the other treatment. The effects of the two treatments may be partially additive, completely additive, or greater than additive. Combination therapy allows the effect of the first treatment to still be detectable when the second treatment is administered.

[0523] In some embodiments, the method further includes administering a second therapeutic agent to the subject. In some embodiments, the antibody, composition, or conjugate disclosed herein is administered before, substantially simultaneously with, or after the administration of the second therapeutic agent.

[0524] In some implementations, the second therapeutic agent includes, but is not limited to, antibiotics or antibacterial agents, antiemetics, antifungals, anti-inflammatory agents, antiviral agents, immunomodulators, cytokines, antidepressants, hormones, alkylating agents, antimetabolites, antitumor antibiotics, antimitotics, topoisomerase inhibitors, cell growth inhibitors, anti-invasive agents, anti-angiogenic agents, inhibitors of growth factor function inhibitors of viral replication, viral enzyme inhibitors, anticancer agents, alpha-interferon, beta-interferon, ribavirin, hormones, cytokines, and other Toll-like receptor modulators.

[0525] Example

[0526] The embodiments of this application will be described in detail below with reference to examples. Those skilled in the art will understand that the following examples are only for illustrating this application and should not be regarded as limiting the scope of this application. Unless otherwise specified in the examples, conventional conditions or conditions recommended by the manufacturer are followed. Reagents or instruments used without specified manufacturers are all commercially available conventional products. Unless otherwise specified, the listed quantities are based on total weight and described in parts by weight. This application should not be construed as being limited to the specific embodiments described. In the result tables shown in the following examples of this application, the control antibody in each row and the subsequent test antibody are from the same batch of experiments.

[0527] Materials and Methods

[0528] 1. mRNA preparation and lipid nanoparticle (LNP) packaging

[0529] Reagents and materials used

[0530] Phusion Flash High-Fidelity PCR Premix, ClonExpressUltraOneStepCloningKit, Gel Extraction Kit (250), Endotoxin-Free Plasmid Large-Scale Extraction Kit, HindIII-HF, T7 High Yield RNA Transcription Kit, Vaccinia Capping Enzyme, E. coli Poly(A)Polymerase, mRNA Cap 2')-O-Methyltransferase, VAHTS RNA Clean Beads, Agilent RNA 6000Nano Kit.

[0531] Experimental methods

[0532] The Human CD200R1 (Uniprot ID: Q8TD46-4, SEQ ID NO: 1) sequence was constructed into the pSP73 mRNA preparation vector (Human CD200R1-pSP73, hereinafter referred to as huCD200R1-pSP73). The constructed huCD200R1-pSP73 vector was subjected to plasmid extraction and linearized using HindIII-HF restriction enzyme. The linearized product was recovered in liquid form. The linearized product was transcribed in vitro using the T7 High Yield RNA Transcription Kit. Subsequently, enzymatic capping and tailing of the linearized mRNA product was performed using two kits: E. coli Poly(A) Polymerase and mRNA Cap 2'-O-Methyltransferase. The mRNA-related products were purified using VAHTS RNA Clean Beads. The quality of the prepared mRNA was evaluated using three methods: agarose gel electrophoresis, 2100 expression, and cellular expression. Qualified samples are then sent to the supplier for lipid nanoparticle (LNP) packaging. The main quality control parameters for LNP samples include: particle size (60-200 nM), polydispersity index (PI) <0.3, zeta potential (neutral, -20-20 mV), and encapsulation efficiency (>80%). Qualified LNP samples will then be used for animal immunization.

[0533] 2. Animal immunization and potency determination

[0534] Related antigens and sequences:

[0535] CD200R1 (Human, Full Length): SEQ ID NO:1

[0536] CD200R1 (Human, ECD): SEQ ID NO:2

[0537] CD200R1 (Crab-eating macaque, full length): SEQ ID NO:3

[0538] CD200R1 (Crab-eating macaque, ECD): SEQ ID NO:4

[0539] CD200R1 (mouse, full length): SEQ ID NO:5

[0540] CD200R1 (mouse, ECD): SEQ ID NO:6

[0541] CD200 (human, ECD): SEQ ID NO:7

[0542] CD200RLa (human): SEQ ID NO:8

[0543] CD200RLa (Crab-eating Monkey): SEQ ID NO:9

[0544] Experimental methods:

[0545] Female BALB / c mice aged 6-8 weeks were selected as immunization animals. Human CD200R1 mRNA LNP samples were diluted to a concentration of 20 μg / mL for immunization. Muscle tissue was used for immunization (100 μL / mouse), and blood was collected after four immunizations to determine the titer. Serum titer levels were detected by flow cytometry using a stable cell line (huCD200R1-HEK293).

[0546] 3. Antibody molecule screening and sequence acquisition

[0547] Reagents and materials used:

[0548] Hybri-Max Red Blood Cell Lysis Buffer TM EasySep TM Mouse B Cell Isolation Kit (Stemcell), Trypan Blue Solution 0.4%, PE anti-His Tag Antibody, Ovalbumin-Biotin, Hu-CD200R1-His (SinoBiological), Chromium Next GEM Single Cell 5'Reagents Kits v2 (Dual Index).

[0549] Experimental methods:

[0550] Spleens were harvested from mice with high immune response levels. 2 ml of RPMI 1640 + 10% FBS medium was added, and the spleen tissue was gently homogenized. The medium was repeatedly changed to a final volume of 20 ml. Red blood cell lysis buffer was added to the prepared spleen tissue cell suspension, and lysis was performed for 3 min. The reaction was then terminated with stop solution, and the remaining cells were collected by filtration. The cells were then processed using EasySep. TMThe Mouse B Cell Isolation Kit was used to enrich B cells in prepared tissue cell suspensions and detect cell viability. Following the instructions, appropriate amounts of PE anti-His Tag Antibody and Human CD200R1-His (hereinafter referred to as Hu-CD200R1-His) protein were added to the B cell suspensions to enrich antigen-specific B cells. After sorting the antigen-specific B cells by flow cytometry, 10X single-cell experiments were immediately performed. Single-cell 5'VDJ libraries were constructed from the enriched antigen-specific B cells using the Chromium Cnotroller instrument platform and Chromium Next GEM Single Cell 5'Reagents Kits v2 (Dual Index). The constructed 5'VDJ libraries were subjected to next-generation sequencing (NGS), and the NGS data were analyzed using Cellranger software to obtain the specific sequence information of the antibody molecules.

[0551] 4. Determination of anti-CD200R1 antibody affinity (KD)

[0552] Reagents and materials used: Protein A probe, 96-well reaction plate, MAX plate, Regeneration Buffer, Q buffer (PBS (10mM pH 7.4) + 0.02% Tween + 0.2% BSA).

[0553] Experimental methods:

[0554] Antibody binding was achieved using a GatorPrime instrument with Protein A probe. The antigen was serially diluted, and the affinity between the antibody and antigen was measured. Q buffer was used as a diluent and neutralizing solution to dilute the antibody and wash the probe; 200 μL of sample was added to each 96-well plate; 250 μL of sample was added to each Max plate (probes must be placed in the Max plate). Samples and buffers were equilibrated to room temperature before the experiment, and the instrument was preheated for 1 hour. Protein A probes were added to the Max plates, along with two columns of Q buffer and one column of Regeneration Buffer. The antibody was diluted to 2 μg / mL; the antigen Hu-CD200R1-His was diluted 2-fold starting at 30 μg / mL for a total of 8 wells. Three columns of Q buffer were added to each 96-well plate; the diluted antibody and antigen were added to the 96-well plates according to the layout (8 antibody samples per column, all at the same concentration). According to the instrument operating instructions, set the following parameters: Pre-wet: 300s, 96-well plate shake: 400RPM, Max plate setting: 1000RPM, Baseline: 120s 1000RPM, Loading: 120s 1000RPM, Baseline: 120s 1000RPM, Association: 300s 1000RPM, Dissociation: 600s 1000RPM. After setting the sample information (name, concentration, molecular weight) in the software, perform antibody kinetics determination; after the program finishes running, calculate the affinity of the antibody to be tested.

[0555] 5. Antigen-anti-CD200R1 antibody binding ability assay (ELISA)

[0556] Antibodies used: Human IgG4, kappa Isotype Control (SinoBiological), Goat anti-human IgG (H+L)HRP.

[0557] Reagents and materials used: TMB chromogenic solution, stop solution, BSA, PBST, PBS, Recombinant Human CD200R Protein, HPLC-verified, and ELISA plates.

[0558] Experimental methods:

[0559] CD200R1-related protein was diluted to 0.5 μg / ml with PBS and added to wells (100 μl / well). The plates were incubated overnight at 4°C. After washing three times with PBST solution, blocking buffer was added for blocking (37°C, 2 h). After blocking, the plates were washed three times with PBST solution and patted dry. The antibody to be screened was diluted 5-fold from 5 μg / ml to 7 spots, with the blank dilution used as the zero point. The diluted antibody was added to the blocked wells and incubated (37°C, 1 h). After incubation, the plates were washed and the secondary antibody (Goat anti-human IgG(H+L)HRP) was added. Incubation was continued at 37°C for 1 h. The plates were washed and patted dry. TMB chromogenic buffer was added and incubated at room temperature for 15 min. Stop solution was then added, and the OD450 value was read using a microplate reader. The experimental results were statistically analyzed.

[0560] 6. Assay for anti-CD200R1 antibody cell binding ability (FACs binding)

[0561] Cells used: Human-CD200R1-HEK293, Cynomolgus macaques-CD200R1-HEK293 (hereinafter referred to as huCD200R1-HEK293; cynoCD200R1-HEK293); cell maintenance medium was DMEM+10% FBS+2μg / mL puromycin, and experimental medium was DMEM+10% FBS.

[0562] Antibodies used: Goat anti-Human IgG Fc Recombinant Secondary Antibody, PE, Human IgG4, kappa Isotype Control (SinoBiological).

[0563] Reagents and materials used: PBS, FBS, DMEM, Zombie Violet TM Fixable Viability Kit, 0.25% Trypsin-EDTA (1x), U-shaped 96-well plate.

[0564] Experimental methods:

[0565] DNA encoding the proteins Hu-CD200R1 (Uniprot ID: Q8TD46-4; SEQ ID NO:1) and Cyno-CD200R1 (Uniprot ID: G7NZT0; SEQ ID NO:3) was integrated into the genome of HEK293 cell line using a lentiviral vector system. Single-cell positive clones of the target proteins, huCD200R1-HEK293 and cynoCD200R1-HEK293, were screened using puromycin pressurization and flow cytometry. When cell confluence exceeded 90%, the cell line was digested with 0.25% Trypsin-EDTA, and the post-digestion cell density was adjusted to 2 x 10⁻⁶ cells / cells. 6 1 x 10^6 antibodies / ml. Dilute the antibody to be screened, starting from 200 nM and diluting 5-fold for a total of 7 spots; add 1 x 10^6 antibodies to each well of a 96-well plate. 5 Cells (50 μL / well) were added, and serially diluted candidate antibodies were added and incubated in the dark (4°C, 60 min). After washing the samples, an appropriate amount of fluorescent secondary antibody and inactivated / deactivated dye were added and incubated (4°C, 30 min). The samples were washed three times with FACs buffer (350 g, 5 min) and then analyzed by flow cytometry.

[0566] 7. Anti-CD200R1 antibody epitope grouping determination

[0567] Reagents and materials used: His probe, 96-well reaction plate, MAX plate, Regeneration Buffer (R Buffer), Q buffer (PBS (10mM pH 7.4) + 0.02% Tween + 0.2% BSA).

[0568] Experimental methods:

[0569] The GatorPrime instrument platform was selected for antibody epitope grouping experiments. In the Max plate, one column was selected to add Q Buffer, and the corresponding probes were transferred to the wells to form the probe column. Simultaneously, one column was selected as the neutralization column (Q Buffer) and another as the regeneration column (R Buffer). In the sample plate (using 8 antibodies as an example), the first column was filled with Q Buffer and designated as the Baseline column; the second column was filled with the corresponding antigen (100-200 nM) and designated as the loading column; the third column was filled with all the antibodies to be tested (10 μg / ml) and designated as the Association 1 column; and the fourth to eleventh columns were each filled with the same antibody (10 μg / ml) and designated as the Association 2 column. The Tandem mode was selected, sample names were entered, and the software program was set up. During software program setup, experimental times and steps could be changed. The antigen solidification time could be evaluated based on preliminary experimental results (antigen solidification height should be 0.3-0.4 nm); antibody 1 binding required saturation. After setup, all plates were placed in the instrument, and the program was run.

[0570] 8. Assay for the non-specific binding ability (FACs) of anti-CD200R1 antibody to cells.

[0571] Cells used: HEK293. Cell maintenance medium was DMEM + 10% FBS + 2 μg / mL puromycin, and experimental medium was DMEM + 10% FBS.

[0572] Antibodies used: Goat anti-Human IgG Fc Recombinant Secondary Antibody, PE, Human IgG4, kappa Isotype Control (SinoBiological).

[0573] Reagents and materials used: PBS, FBS, DMEM, Zombie Fixable Viability Kit, 0.25% Trypsin-EDTA (1x), U-shaped 96-well plate.

[0574] Experimental methods:

[0575] When HEK293 cell adhesion exceeded 90%, the cell line was digested with 0.25% Trypsin-EDTA; and the post-digestion cell density was adjusted to 2 x 10⁻⁶ cells / year. 6 1 x 10^6 antibodies / ml. Dilute the antibody to be screened and add 1 x 10^6 antibodies to each well of a 96-well plate. 5Cells (50 μL / well) were added, and serially diluted candidate antibodies were added and incubated in the dark (100 nM, 4 °C, 60 min). After washing the samples, an appropriate amount of fluorescent secondary antibody and inactivated / deactivated dye were added and incubated (4 °C, 30 min). The samples were washed three times with FACs buffer (350 g, 5 min) and then analyzed by flow cytometry.

[0576] 9. Reagents and materials used for determining the non-specific binding ability of anti-CD200R1 antibody homologous proteins

[0577] Hu-CD200RLa (SinoBiological), Cy-CD200RLa (SinoBiological), His probe, 96-well reaction plate, MAX plate, Regeneration Buffer, Q buffer (PBS (10mM pH 7.4) + 0.02% Tween + 0.2% BSA).

[0578] Experimental methods

[0579] The GatorPrime instrument platform was selected for the non-specific binding affinity assay of antibody homologous proteins. In the Max plate, one column was selected for adding Q Buffer, and the corresponding probes were transferred to the wells to form the probe column. Simultaneously, one column was selected as the neutralization column (Q Buffer) and another as the regeneration column (R Buffer). In the sample plate, the first column was added with Q Buffer and designated as the baseline column, the second column was added with the corresponding antigen (5 μg / mL) and designated as the loading column, and 200 μL of all the antibodies to be tested were added to the remaining wells, resulting in a final concentration of 200 nM (designated as the Association column). The software program was set up according to the antibody affinity assay mode. During software setup, the experimental time and additional steps could be modified. The antigen solidification time could be evaluated based on preliminary experimental results (the required antigen solidification height is 0.3-0.4 nm). After setup, all plates were placed in the instrument, and the program was run.

[0580] 10. Determination of the ability of anti-CD200R1 antibody to block receptor binding.

[0581] Reagents and materials used: Hu-CD200R1-His (SinoBiological), HuCD200-Fc, His probe, 96-well reaction plate, MAX plate, Regeneration Buffer, Q buffer (PBS (10mM pH 7.4) + 0.02% Tween + 0.2% BSA).

[0582] Experimental methods:

[0583] The GatorPrime instrument platform was selected for the antibody blocking receptor-ligand binding capacity assay. In the Max plate, one column was selected for adding Q Buffer, and the corresponding probes were transferred to the wells to form the probe column. Simultaneously, one column was selected as the neutralization column (Q Buffer) and one as the regeneration column (R Buffer). In the sample plate (using 8 antibodies as an example), the first column was filled with Q Buffer and designated as the Baseline column; the second column was filled with the receptor huCD200R1-His and designated as the loading column; the third column was filled with the ligand HuCD200-FC (10ug / ml) and designated as the Association 1 column; the remaining wells were filled with the antibody to be tested and designated as the Association 2 column. The tandem mode was selected, sample names were entered, and the software program was set up. During software program setup, experimental times and steps could be changed. The antigen solidification time could be evaluated based on preliminary experimental results (antigen solidification height required to be 0.3-0.4nm); antibody 1 binding required to be saturated. After setting up, all plates were placed in the instrument, and the program was run.

[0584] 11. IL-8 release assay

[0585] Cells used: Human CD200R1 overexpressing cells (Human CD200R1 U937). The culture medium used to maintain Human CD200R1 U937 cells (hereinafter referred to as huCD200R1-U937) was RPMI 1640 + 10% FBS + 2ug / ml puromycin, and the experimental culture medium was RPMI 1640 + 10% FBS.

[0586] Antibodies used: I-4P (IgG4SP), Human IgG4, kappa Isotype Control (SinoBiological).

[0587] Reagents used: Lipopolysaccharide (LPS), Phomorpho-Myristate Acetate (PMA), Puromycin, Human IL-8 / CXCL8 ELISA Kit (SinoBiological)

[0588] Experimental methods:

[0589] Screening for antibodies that can deactivate LPS-induced IL-8 cytokine secretion in HuCD200R1-U937 cells.

[0590] First, huCD200R1-U937 cells were adjusted to a density of 5 x 10⁵ cells / ml using RPMI 1640 medium containing 40 nM PMA, and an appropriate amount was transferred to a T75 culture flask and incubated (37°C, 24 h). After incubation, the cells were centrifuged to remove the supernatant, and the cell suspension was adjusted to a density of 1 x 10⁶ cells / ml and added to a 96-well plate (100 μL / well). Simultaneously, the antibody to be screened was diluted in eight gradients (175, 58.3325, 19.445, 6.4825, 2.16, 0.72, 0.24, and 0.08 nM) and added to the cells (50 μL / well), and incubated at 37°C for 60 min. After incubation, 200 ng / mL LPS dilution was added to the cells (50 μL / well), and the processed cell plates were then incubated at 37°C for 24 h. Finally, the cell plates were centrifuged (500g, 10min), and the cell supernatant was transferred to new wells for IL-8 content detection. IL-8 content was detected using the purchased Human IL-8 / CXCL8 ELISA Kit (SinoBiological), following the kit instructions (cell supernatant diluted 50-fold before detection). After detection, the absorbance (OD450) of each standard and sample was calculated, and the IL-8 content in the sample was deduced from the standard curve. The control stimulation group consisted of LPS-stimulated cells (untreated with antibody); the treatment group consisted of LPS-stimulated cells (treated with antibody)...; the control unstimulated group consisted of unstimulated cells (untreated with antibody)... Based on the calculated IL-8 content, the IL-8 secretion inhibition rate was calculated using the following formula: (Control stimulation group - Treatment group) / (Control stimulation group - Control unstimulated group).

[0591] 12. Anti-CD200R1 antibody inhibits contact hypersensitivity in dual-humanized mice.

[0592] Reagents and materials used

[0593] hCD200 / hCD200R mice (C57BL / 6), wild-type C57BL / 6 mice, OXA (oxazolone), acetone, olive oil, precision electronic balance, thickness gauge, and crestorosine ointment.

[0594] Experimental methods

[0595] To demonstrate the anti-inflammatory effect of anti-CD200R1 antibodies, 6-8 week old female hCD200 / hCD200R (C57BL / 6) mice (Biocytogen) were purchased. After a week of acclimatization, all animals underwent dorsal hair removal on day 1. On day 0, after randomization according to body weight, the mice were sensitized with 3% OXA (20 μL for ears + 200 μL for back) and administered intraperitoneally (10 mg / kg). The positive control group received criborone ointment (a PDE4 inhibitor; 6 mg for ears, 18 mg for back / mouse / dose). The model group received PBS concurrently. From day 8 to day 21, 0.1% OXA challenge was performed daily (20 μL for ears + 200 μL for back). The antibody administration group received the drug twice a week (BIW, ip, 10 mg / kg), and the positive control group received criborone ointment twice daily. The experimental animals underwent weight monitoring three times a week (10 times in total), ear thickness measurement three times a week (10 times in total), and ear and back scoring three times a week (10 times in total). Additionally, photographs were taken of the ear and back induction sites once a week (three times in total). After the efficacy evaluation was completed on Day 21, the mice were euthanized and relevant tissue and blood samples were collected.

[0596] 13. Control antibody

[0597] Anti-CD200R antibodies I-4P, 23ME-00610, and GS5305 were selected as control antibodies, and their sequence number information is shown in Table 2 below.

[0598] Table 2. Control antibody sequences

[0599] Example 1. mRNA Immunization and Antibody Sequence Generation

[0600] Mice were immunized and their titers were evaluated using the experimental methods described above. The results showed that all immunized mice produced a high immune response, indicating that immunized mice can be used as raw materials for screening antigen-specific antibodies. Spleen tissue from immunized mice was harvested and prepared into B cell suspensions. Antibody clones were obtained by flow cytometry sorting and sequencing. The obtained positive clones were further processed into chimeric antibodies, with their variable regions ligated into the constant region of human IgG4 (S228P mutation), yielding chimeric antibodies mhb001-mhb0020, mhb0024, mhb0059, mhb0045, mhb0048, mhb0060, mhb0066, mhb0068, mhb0069, SKG0002-SKG0006, SKG0011-SKG0019, SKG0036, and SKG0048. The chimeric antibodies and their sequence numbers are shown in Table 3.

[0601] Table 3 Antibody SEQ ID NO (CDR defined according to Kabat coding rules)

[0602] Example 2. Affinity determination of anti-CD200R1 antibody

[0603] Following the method described above, the affinity (KD) between the antibody samples and Hu-CD200R1 protein was determined using the Gatorprime instrument platform. Existing antibody I-4P was used as a control. To ensure the accuracy of the experimental system, the affinity of control antibody I-4P for Hu-CD200R1 was also measured. The experimental results showed that the affinity of control antibody I-4P was consistent with the publicly available information (CN112739422A), indicating that the affinity determination method was correct. The specific KD values ​​of the screened antibodies are shown in Table 4.

[0604] Table 4

[0605] " / " indicates that the value was not detected; some molecules are fast dissociation molecules, so the Kon and Koff values ​​cannot be detected; KD is calculated using steady-state methods.

[0606] Example 3. Validation of antibody binding activity using huCD200R1-HEK293 cells.

[0607] Following the methods described above, the binding activity of the screening antibodies to the Hu-CD200R1 protein was determined at the cellular level. A stable cell line, huCD200R1-HEK293, was constructed. Different concentrations of the screening antibodies were incubated with huCD200R1-HEK293 cells, and the antibody binding levels on the cells were detected by flow cytometry, with EC50 values ​​calculated. The results showed that all screening antibodies exhibited good activity in huCD200R1-HEK293 cells, with target binding activity superior to or no less than that of the control antibody I-4P. Most of these antibodies showed significantly better binding activity than the control antibodies I-4P and GS5305. Specific data are shown in Figure 1 and Table 5.

[0608] Table 5

[0609] Example 4. Verification of antibody binding activity using CynoCD200R1-HEK293 cells.

[0610] Following the methods described above, the species-cross-binding activity of the screening antibodies against Cyno-CD200R1 protein was determined at the cellular level. A stable cell line, CynoCD200R1-HEK293, was constructed. Different concentrations of the screening antibodies were incubated with CynoCD200R1-HEK293 cells, and the antibody binding levels on the cells were detected by flow cytometry, with EC50 values ​​calculated. The results showed that most of the screened molecules exhibited significant human-monkey cross-activity, and their binding to Cyno-CD200R1 protein was superior to that of the control antibody. Specific data are shown in Figure 2 and Table 6.

[0611] Table 6

[0612] Example 5. Measurement of the binding ability of anti-CD200R1 antibody to antigen (hu-CD200R1) (ELISA)

[0613] Following the method described above, the binding activity of the screening antibody to Hu-CD200R1 protein was determined at the ELISA level. Hu-CD200R1 protein (SEQ ID NO:2) was expressed and purified. Different concentrations of the screening antibody were incubated with Hu-CD200R1 protein, and the binding level of the antibody to the protein in vitro was detected using a microplate reader. The EC50 value was calculated. The results showed that the screening antibody had good binding activity to Hu-CD200R1 protein, and its target binding activity was superior to or no less than that of the control antibody I-4P. Most of the antibodies showed significantly better binding activity than the control antibody I-4P. Specific data are shown in Figure 3 and Table 7.

[0614] Table 7

[0615] Example 6. Measurement of the binding ability of anti-CD200R1 antibody to antigen (cyno-CD200R1) (ELISA)

[0616] Following the method described above, the binding activity of the screening antibodies to Cyno-CD200R1 protein was determined at the ELISA level. Cyno-CD200R1 protein (SEQ ID NO:4) was expressed and purified. Different concentrations of the screening antibodies were incubated with Cyno-CD200R1 protein, and the binding level of the antibodies to the protein in vitro was detected using a microplate reader. The EC50 value was calculated. The results showed that most of the screening antibodies had good binding activity to Cyno-CD200R1 protein, and their target binding activity was superior to or no less than that of the control antibody I-4P. Most of the antibodies showed significantly better binding activity than the control antibody I-4P. Specific data are shown in Figure 4 and Table 8.

[0617] Table 8

[0618] Example 7. Validation of non-specific binding activity of antibody in HEK293 cells.

[0619] To determine at the cellular level whether antibodies exhibit non-specific binding to HEK293 cells, the aforementioned method was used. HEK293 cells were incubated with antibodies (100 nM), and flow cytometry was used to detect the presence of binding signals on the cells. The results showed that only mhb0024, SKG0015, SKG0002, and mhb0060 of the antibody molecules exhibited weak non-specific binding to HEK293 cells, while the remaining molecules did not bind non-specifically. Specific data are shown in Figure 5.

[0620] Example 8. Anti-CD200R1 antibody epitope grouping determination

[0621] Different antibodies may bind to different epitopes of an antigen, causing different conformational changes in the antigen and thus leading to differences or intensities in downstream signal transduction. Therefore, to further screen lead antibody molecules, epitope grouping experiments were performed according to the method described above. The three control antibodies, I-4P, GS5305, and 23ME-00610, bind to different epitopes and exert different functions. Therefore, these three control antibodies were introduced into the experimental group as a reference, thereby narrowing down the scope of subsequent lead molecule screening.

[0622] Epitope grouping experiments were performed on all antibody molecules using the Gatorprime instrument platform. After the experiment, a threshold was set based on the signal values ​​of the diagonal self-pairing, and the highest signal value in the diagonal was selected as the experimental threshold. When analyzing the data, epitopes were grouped according to the inhibition rate between two molecules: inhibition rate <30% indicated fully competitive epitopes, inhibition rate between 30-70% indicated partially competitive epitopes, and inhibition rate >70% indicated different epitopes. Specific results are shown below (Table 9). Molecules with the same epitope are displayed in the same column (italicized, bold, and underlined molecules indicate partial competition with other molecules for that epitope). Specifically, in group 1, SKG0012 partially competes with other molecules; in group 2, mhb0011, mhb0013, and SKG0015 partially compete with other molecules. Among these, mhb0012, mhb0020, SKG0004, mhb0059, and mhb0060 are independent epitopes.

[0623] Table 9

[0624] Example 9. Detection of the activity of anti-CD200R1 antibody in blocking the binding of CD200 and CD200R1

[0625] CD200 is the natural ligand of CD200R1, both belonging to the immunoglobulin superfamily. Both contain two Ig-like domains, and their interaction alters downstream signaling pathways, thus affecting cellular function. A Gatorprime instrument was used to determine whether candidate antibodies bind to CD200R1 protein in the presence of ligand saturation. Hu-CD200R1-His protein was captured using an Anti-His probe, and after binding to a certain height, HuCD200-Fc (assocation 1) was captured. When the association 1 signal reached saturation, the signal (shift (nm)) of the candidate antibody was captured (assocation 2). If the candidate antibody could bind to the captured hu-CD200R1 with a high binding response value, the binding epitope of the antibody was non-competitive with the binding site of hu-CD200. Conversely, the binding epitope of the candidate antibody was competitive with the binding site of hu-CD200. This method was used to evaluate whether the candidate antibody had a competitive epitope. Since I-4P and GS5305 are non-competitive antibodies, their response values ​​are used as reference values ​​(shift(nm)). If the response value of the screened antibody is equal to or greater than that of the control antibody, the antibody is considered to be a non-competitive antibody; the remaining antibodies are judged to be pending (indicated by " / "). For details, please refer to Table 10.

[0626] Table 10

[0627] Example 10. Screening for antibodies that relieve LPS-induced IL-8 secretion

[0628] Based on the initial screening results, preferred molecules were selected for IL-8 cytokine release experiments, and lead molecules were further screened. Since CD200R1 is a highly expressed inhibitory target in myeloid cells, it affects cytokine expression through the CD200-CD200R1-DOK2-RasGAP-NFκB signaling pathway, thereby influencing the levels of inflammatory factors in vivo. Considering that IL-8 is a major effector in this signaling pathway and is associated with the development of various diseases as a cytokine, developing a screening system to deactivate LPS-induced IL-8 cytokine release from HuCD200R1-U937 cells has significant guiding implications.

[0629] The assay was performed according to the methods described above. To verify the correctness of the experimental system, the molecular activity of the control antibody I-4P was evaluated simultaneously during the screening of the lead molecule. The results showed that the experimental system could reproduce the molecular function of the control antibody I-4P, and the functional activity of the candidate antibody was superior to that of the control antibody. Specific results are shown in Figure 6 and Table 11, where Table 11 shows the minimum inhibition rate, maximum inhibition rate, and IC50 for each test sample; Figure 6 shows the inhibition rate corresponding to each concentration of each test sample.

[0630] Table 11 Assay for IL-8 secretion inhibition

[0631] Example 11. Detection of the activity of anti-CD200R1 antibody in blocking the binding of CD200 and CD200R1 at the cellular level

[0632] Based on the preliminary screening data, the preferred antibodies were initially identified, and further ligand blocking assays were performed on hu-CD200R1-HEK293 cells using FACs (Fluid-Assisted Cell Blocking) experiments. Different concentrations of the test antibodies were incubated with the cells (4℃, 60 min), washed, and then incubated with 100 μL of the ligand HuCD200-His (4 μg / ml) (4℃, 60 min). Finally, the relevant detection antibodies were added, and the antibody blocking activity was detected. The results are shown in Figure 7 and Table 12. The two candidate antibodies, SKG0016 and SKG0048, had epitope characteristics consistent with the control antibodies (I-4P and GS5305), indicating they were non-competitive antibodies. mhb0060 and mhb0066 were partially competitive antibodies, and the remaining candidate antibodies were competitive antibodies.

[0633] Table 12

[0634] Example 12. Humanization Design and Activity Evaluation of SKG0016 Antibody

[0635] After synthesizing all data, SKG0016 was confirmed as the lead molecule. A comprehensive evaluation of the SKG0016 molecule revealed a risk site (NG) in its heavy chain CDR2 region; therefore, a NE mutation was introduced to obtain the SKG0016-mut molecule. Simultaneously, to address the immunogenicity issue of the murine molecule, the SKG0016 sequence was aligned using Igblast to identify the Homo sapiens germline with the highest similarity. Humanization of the SKG0016 molecule was then performed using CDR Graft-related methods, resulting in humanized molecules SKG0016-H7, SKG0016-H11, SKG0016-H13, and SKG0016-H17. The sequence information of the humanized molecules is shown in Table 13. The activity of the humanized molecules was evaluated (KD, FACs binding, and IL-8 release inhibition experiments) using the same methods as described in the previous examples. Experimental results show that humanized molecules with functions and activities comparable to the parent molecule have been obtained (Figures 8 and 9, Tables 14-16).

[0636] Table 13

[0637] Table 14. Determination of humanized anti-affinity

[0638] Table 15. Antibody binding activity verified in huCD200R1-HEK293 cells.

[0639] Table 16. Assay for IL-8 secretion inhibition

[0640] Example 13. Anti-CD200R1 antibody inhibits contact hypersensitivity in dual-humanized mice

[0641] The specific protocol for the animal experiments is shown in Figure 10. The results showed that all animals were in good condition with normal weight fluctuations. Compared to the control group (Group 1, normal mice), the model group mice (Group 2) showed a significant increase in all disease scores. Meanwhile, the criborone (PDE4 inhibitor) treatment group (Group 3) showed a significant decrease in disease scores compared to Group 2, indicating successful establishment of the disease model. Further analysis revealed that Group 6 (SKG0016) showed the best therapeutic effect among the anti-CD200R1 antibody treatment groups, comparable to or even better than the small molecule treatment group; it was also significantly superior to the control antibodies GS5305 (Group 5) and I-4P (Group 4). Specific experimental results are shown in Figure 11. These results demonstrate that the chimeric antibody SKG0016 has a significant therapeutic effect in treating a mouse model of exposure to hypersensitivity diseases.

[0642] Sequence information:

Claims

1. An anti-CD200R1 antibody or its antigen-binding fragment, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (1) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:301, 302 and 303 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:306, 307 and 308 respectively. (2) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:301, 422 and 303 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:306, 307 and 308 respectively. (3) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:31, 32 and 33 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:36, 37 and 38 respectively. (4) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:41, 42 and 43 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:46, 47 and 48 respectively. (5) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:51, 52 and 53 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:56, 57 and 58 respectively. (6) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:61, 62 and 63 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:66, 67 and 68 respectively. (7) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:71, 72 and 73 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:76, 77 and 78 respectively. (8) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:81, 82 and 83 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:86, 87 and 88 respectively. (9) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:91, 92 and 93 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:96, 97 and 98 respectively. (10) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:101, 102 and 103 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:106, 107 and 108 respectively. (11) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:111, 112 and 113 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:116, 117 and 118 respectively. (12) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:121, 122 and 123 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:126, 127 and 128 respectively. (13) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:131, 132 and 133 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:136, 137 and 138 respectively. (14) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:141, 142 and 143 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:146, 147 and 148 respectively. (15) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:151, 152 and 153 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:156, 157 and 158 respectively. (16) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:161, 162 and 163 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:166, 167 and 168 respectively. (17) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:171, 172 and 173 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:176, 177 and 178 respectively. (18) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:181, 182 and 183 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:186, 187 and 188 respectively. (19) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:191, 192 and 193 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:196, 197 and 198 respectively. (20) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:201, 202 and 203 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:206, 207 and 208 respectively; (21) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:211, 212 and 213 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:216, 217 and 218 respectively. (22) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:221, 222 and 223 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:226, 227 and 228 respectively; (23) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:231, 232 and 233 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:236, 237 and 238 respectively; (24) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:241, 242 and 243 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:246, 247 and 248 respectively. (25) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:251, 252 and 253 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:256, 257 and 258 respectively. (26) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:261, 262 and 263 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:266, 267 and 268 respectively. (27) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:271, 272 and 273 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:276, 277 and 278 respectively; (28) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:281, 282 and 283 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:286, 287 and 288 respectively; (29) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:291, 292 and 293 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:296, 297 and 298 respectively; (30) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:311, 312 and 313 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:316, 317 and 318 respectively. (31) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:321, 322 and 323 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:326, 327 and 328 respectively; (32) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:331, 332 and 333 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:336, 337 and 338 respectively; (33) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:341, 342 and 343 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:346, 347 and 348 respectively. (34) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:351, 352 and 353 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:356, 357 and 358 respectively. (35) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:361, 362 and 363 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:366, 367 and 368 respectively. (36) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:371, 372 and 373 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:376, 377 and 378 respectively. (37) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:381, 382 and 383 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:386, 387 and 388 respectively. (38) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:391, 392 and 393 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:396, 397 and 398 respectively. (39) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:401, 402 and 403 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:406, 407 and 408 respectively. (40) The VH comprises HCDR1, HCDR2, and HCDR3 having amino acid sequences as shown in SEQ ID NO:411, 412, and 413, respectively; and the VL comprises LCDR1, LCDR2, and LCDR3 having amino acid sequences as shown in SEQ ID NO:416, 417, and 418, respectively; or (41) The VH comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO:481, 482 and 483 respectively; and the VL comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO:486, 487 and 488 respectively.

2. The antibody of claim 1 or its antigen-binding fragment, wherein: (1) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:300; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:305; (2) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:420; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:425; (3) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:430; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:435; (4) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:440; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:445; (5) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:450; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:455; (6) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:460; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:465; (7) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:30; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:35; (8) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:40; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:45; (9) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:50; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:55; (10) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:60; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:65; (11) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:70; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:75; (12) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:80; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:85; (13) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:90; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:95; (14) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:100; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:105; (15) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:110; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:115; (16) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:120; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:125; (17) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:130; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:135; (18) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:140; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:145; (19) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:150; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:155; (20) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:160; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:165; (21) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:170; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:175; (22) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:180; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:185; (23) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:190; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:195; (24) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:200; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:205; (25) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:210; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:215; (26) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:220; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:225; (27) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:230; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:235; (28) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:240; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:245; (29) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:250; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:255; (30) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:260; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:265; (31) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:270; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:275; (32) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:280; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:285; (33) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:290; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:295; (34) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:310; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:315; (35) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:320; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:325; (36) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:330; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:335; (37) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:340; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:345; (38) The VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:350; and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:355; (39) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:360; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:365; (40) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:370; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:375; (41) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:380; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:385; (42) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:390; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:395; (43) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:400; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:405; (44) The VH comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:410; and the VL comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:415; or (45) The VH contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:480; and the VL contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:

485.

3. The antibody or antigen-binding fragment thereof according to any one of claims 1 or 2, wherein the antibody is a mouse antibody, a chimeric antibody or a humanized antibody.

4. The antibody or antigen-binding fragment thereof according to any one of claims 1-3, wherein the antibody is an isotype selected from IgG, IgA, IgM, IgE and IgD.

5. The antibody or antigen-binding fragment thereof according to any one of claims 1-4, wherein the antibody is a subtype selected from IgG1, IgG2, IgG3 and IgG4.

6. The antibody or antigen-binding fragment thereof of any one of claims 1-5, wherein the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fd', Fv, scFv, ds-scFv and dAb.

7. The antibody or antigen-binding fragment thereof of any one of claims 1-6, wherein it is a monoclonal antibody, a bispecific antibody or a multispecific antibody.

8. The antibody or antigen-binding fragment thereof of any one of claims 1-7, wherein the antibody comprises a heavy chain (HC) and a light chain (LC), wherein: (1) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:304; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:309; (2) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:424; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:429; (3) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:434; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:439; (4) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:444; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:449; (5) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:454; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:459; (6) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:464; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:469; (7) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:34; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:39; (8) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:44; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:49; (9) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:54; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:59; (10) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:64; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:69; (11) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:74; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:79; (12) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:84; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:89; (13) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:94; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:99; (14) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:104; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:109; (15) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:114; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:119; (16) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:124; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:129; (17) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:134; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:139; (18) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:144; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:149; (19) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:154; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:159; (20) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:164; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:169; (21) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:174; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:179; (22) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:184; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:189; (23) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:194; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:199; (24) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:204; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:209; (25) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:214; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:219; (26) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:224; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:229; (27) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:234; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:239; (28) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:244; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:249; (29) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:254; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:259; (30) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:264; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:269; (31) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:274; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:279; (32) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:284; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:289; (33) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:294; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:299; (34) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:314; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:319; (35) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:324; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:329; (36) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:334; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:339; (37) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:344; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:349; (38) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:354; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:359; (39) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:364; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:369; (40) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:374; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:379; (41) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:384; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:389; (42) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:394; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:399; (43) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:404; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:409; (44) The HC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:414; and the LC comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity with SEQ ID NO:419; or (45) The HC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:484; and the LC contains an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:

489.

9. A nucleic acid comprising an antibody or an antigen-binding fragment thereof encoding any one of claims 1-8.

10. A vector comprising the nucleic acid of claim 9.

11. A host cell comprising the nucleic acid of claim 9 or the vector of claim 10.

12. A conjugate comprising an antibody or antigen-binding fragment thereof of any one of claims 1-8, and a chemical moiety conjugated thereto.

13. A pharmaceutical composition comprising (i) an antibody or antigen-binding fragment thereof of any one of claims 1-8, or a conjugate of claim 12; and optionally (ii) a pharmaceutically acceptable carrier or excipient.

14. The pharmaceutical composition of claim 13, further comprising a second therapeutic agent.

15. The pharmaceutical composition of claim 14, wherein the second therapeutic agent is selected from antibodies, chemotherapeutic agents, small molecule drugs, siRNA, and antisense oligonucleotides.

16. A method for treating a disease in a subject, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof of any one of claims 1-8, a conjugate of claim 12, or a pharmaceutical composition of any one of claims 13-15, wherein the disease is a CD200R1-mediated disease and / or a disease associated with CD200R1 expression.

17. The method of claim 16, wherein the disease is selected from inflammatory diseases, autoimmune diseases, allergic diseases, and neurodegenerative diseases.

18. The method of claim 17, wherein the disease is selected from multiple sclerosis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, colitis (e.g., ulcerative colitis), atopic dermatitis, and Parkinson's disease.